## GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2023

Η

#### HOUSE BILL 563

#### Committee Substitute Favorable 6/21/23 Committee Substitute #2 Favorable 8/16/23 Committee Substitute #3 Favorable 9/21/23 Senate Judiciary Committee Substitute Adopted 6/13/24 Senate Finance Committee Substitute Adopted 6/18/24

Short Title:	Hemp-Derived Consumables/Con Sub Changes.	(Public)
Sponsors:		
Referred to:		

### April 5, 2023

1		A BILL TO BE ENTITLED			
2	AN ACT TO	REGULATE THE SALE AND DISTRIBUTION OF HEMP-DERIVED			
3	CONSUMA	BLE PRODUCTS, TO IMPOSE AN EXCISE TAX ON THOSE PRODUCTS,			
4	TO BAN TH	OSE PRODUCTS FROM SCHOOL GROUNDS, TO PLACE TIANEPTINE,			
5	XYLAZINE,	AND KRATOM ON THE CONTROLLED SUBSTANCE SCHEDULES, TO			
6	CREATE TH	IE OFFENSE OF CRIMINAL POSSESSION AND UNLAWFUL SALE OF			
7	EMBALMIN	G FLUID AND TO MAKE OTHER TECHNICAL REVISIONS, AND TO			
8	CREATE N	IEW CRIMINAL OFFENSES FOR EXPOSING A CHILD TO A			
9	CONTROLL	ED SUBSTANCE.			
10	The General Asso	embly of North Carolina enacts:			
11					
12	PART I. REGU	LATION OF HEMP-DERIVED CONSUMABLE PRODUCTS			
13	SECT	<b>TION 1.(a)</b> The General Statutes are amended by adding a new Chapter to read:			
14		" <u>Chapter 18D.</u>			
15	"Regulation of Hemp-Derived Consumable Products.				
16		"Article 1.			
17		"Regulation of Hemp-Derived Consumable Products.			
18	" <u>§ 18D-100. Def</u>	initions.			
19	Unless the co	ntext requires otherwise, the following definitions apply in this Article:			
20	<u>(1)</u>	ALE Division. – As defined in G.S. 18B-101.			
21	<u>(2)</u>	Batch The hemp-derived consumable product produced during a period of			
22		time under similar conditions and identified by a specific code that allows			
23		traceability.			
24	<u>(3)</u>	<u>Department. – The Department of Revenue.</u>			
25	<u>(4)</u>	Distributor A person or entity that delivers or sells hemp-derived			
26		consumable products for the purpose of distribution in commerce.			
27	<u>(4a)</u>	Exit package An opaque bag or other similar opaque covering provided at			
28		the point of sale that satisfies the child-resistant effectiveness standards under			
• •		$16 C E D \le 1700 (15/h)(1)$ when tested in accordance with the requirements			
29		16 C.F.R. § 1700.15(b)(1) when tested in accordance with the requirements			
29 30		of 16 C.F.R. § 1700.20 in which hemp-derived consumable products are			



(6)       Hemp-derived cannabinoid. — Any phytocannabinoid found in hemp, including delta-9 tetrahydrocannabinoit (delta-9 THC), tetrahydrocannabinoit (delta-9 THC), cannabicydol (CBL), cannabicydol (delta-7 THC), cannabicydol (delta-8 tetrahydrocannabinoi (delta-7 THC), cannabinoid derived from hemp and contained in a hemp-derived consumable product.         7       delta-8 tetrahydrocannabinoi (delta-8 THC), or delta-10 tetrahydrocannabinoi (delta-10 THC). This term also includes any swnthetic cannabinoid derived from hemp and contained in a hemp-derived consumable product. A hemp product that is a finished good intended for human ingestion or inhalation that contains a delta-9 THC concentration of not more than three-tenths of one percent (0.3%) on a dry weight basis, but may contain concentrations of other hemp-derived cannabinoids, in excess of that amount. This term does not include hemp products intended for human tecestion, or seeds or seed derived ingredents that are generally recognized as safe by the United States Food and Drug Administration (FDA).         18       (8)       Hemp product.—As defined in G.S. 90-87.         19       (9)       Independent testing laboratory. A laboratory that meets all of the following conditions:         23       13011.3.         24       b. Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable product is heing tested.         26       c. Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable product is heing test		General Assemb	ly Of North Carolina	Session 2023
2       including delta-9 tetrahydrocannabinol (delta-9 THC), tetrahydrocannabinolic         3       acid (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin         4       (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarin         6       (CBN), cannabiciran (CBN), elta-10 tetrahydrocannabiloid (delta-7 THC),         7       delta-8 tetrahydrocannibinol (delta-8 THC), or delta-10 tetrahydrocannibinol         8       (delta-10 THC). This term also includes any synthetic cannabinol derived         9       from hemp and contained in a hemp-derived consumable product.         10       (7)       Hemp-derived consumable product. — A hemp product that is a finished good         11       intended for human ingestion or inhalation that contains a delta-9 THC         12       concentration of not more than three-tenths of one percent (0.3%) on a dry         13       weight basis, but may contain concentrations of other hemp-derived         14       cannabinoids, in excess of that amount. This term does not include hemp         15       products intended for topical application, or seeds or seed derived ingredients         16       that are generally recognized as safe by the United States Food and Drug         17       Independent testing laboratory.—A laboratory that meets all of the following         18       (8)       Hemp product. as defined in G.S. 90-87.         19       (9) </td <td>1</td> <td>(6)</td> <td>Hemp-derived cannabinoid. – Any phytocannabinoid</td> <td>found in hemp.</td>	1	(6)	Hemp-derived cannabinoid. – Any phytocannabinoid	found in hemp.
3       acid (THCA). cannabidiol (CBD), cannabidiolic acid (CBDA), cannabiverol (CBG), cannabiverol (CBC), cannabiverol (CBC), cannabiverol (CBC), cannabiverol (CBDV), cannabiverol (CBC), cannabiverol (CBDV), cannabiverol (CBC), cannabiverol (CBDV), cannabiverol (CBDVV), cannabiverol (CBDV), cannabiverol		<u></u>		
4       (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL),         5       cannabivarin         6       (CBV), cannabicitran (CBT), delta-7 tetralydrocannabiool (delta-7 THC),         7       delta-8 tetrahydrocannibinol (delta-8 THC), or delta-10 tetrahydrocannibinol         8       (delta-10 THC). This term also includes any synthetic cannabinoid derived         9       from hemp and contained in a hemp-derived consumable product.         10       (2)       Hemp-derived consumable productA hemp product that is a finished good         11       intended for human ingestion or inhalation that contains a delta-9 THC         12       concentration of not more than three-tenths of one percent (0.3%) on a dry         13       weight basis, but may contain concentrations of other hemp-derived         14       cannabinoids, in excess of that amount. This term does not include hemp         15       products intended for topical application, or seeds or seed derived ingredients         16       that are generally recognized as affe by the United States Food and Drug         17       Administration (FDA).         18       (8)         19       19         10       Independent testing laboratory. – A laboratory that meets all of the following         10       conditions:         1       a. Holds an ISO 17025 accreditation or is registe				
5       canabivarin (CBV), tetrabydrocannabivarin (THCV), cannabidivarin (CBDV), cannabicitari (CBT), delta-7 tetrahydrocannibinol (delta-7 THC), delta-8 tetrahydrocannibinol (delta-8 THC), or delta-10 tetrahydrocannibinol (delta-10 tetrahydrocananibinol (delta-10 tetrahydrocannibinol tendet tetrahydrocannibinol				
6       (CBDV), cannabicitran (CBT), delta-7 tetrahydrocannibinol (delta-7 THC), delta-8 tetrahydrocannibinol (delta-10 THC). This tern also includes any synthetic cannabinoid derived from hemp and contained in a hemp-derived consumable product.         7       Hemp-derived consumable product. — A hemp product that is a finished good intended for human ingestion or inhalation that contains a delta-9 THC concentration of not more than three-tenths of one percent (0.3%) on a dry weight basis, but may contain concentrations of other hemp-derived cannabinoids, in excess of that amount. This tern does not include hemp products intended for topical application, or seeds or seed derived ingredients that are generally recognized as safe by the United States Food and Drug Administration (TPA).         18       (8)         18       (9)         10       Independent testing laboratory. — A laboratory that meets all of the following conditions:         20       enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         21       b. Does not have a direct or indirect interest in the entity whose product is being tested.         26       c. Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable product. tetrahydrocannabiol concentration sampling and testing using the high-performance chromatography (HPLC) testing method, using the high-performance chromatography (HPLC) testing method, swallowing into the gastrointestinal system or through tissue absorption.         22       for best consumable product.         33       swallowing into the gastorintestinal system or throu				-
7       delta=10 tetrahydrocannibinol (delta=8 THC), or delta=10 tetrahydrocannibinol (delta=10 THC). This term also includes any synthetic cannabinoid derived from hemp and contained in a hemp-derived consumable product.         10       (7)       Hemp-derived consumable product A hemp product that is a fnished good intended for human ingestion or inhalation that contains a delta-9 THC concentration of not more than three-tenths of one percent (0.3%) on a dry weight basis. but may contain concentrations of other hemp-derived cannabinoids, in excess of that amount. This term does not include hemp products intended for topical application, or seeds or seed derived ingredients that are generally recognized as safe by the United States Food and Drug Administration (FDA).         18       (8)       Hemp product As defined in G.S. 90-87.         19       (9)       Independent testing laboratory A laboratory that meets all of the following conditions:         21       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         24       b.       Does not have a direct or indirect interest in the entity whose product is is being tested.         26       c.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable product is the gastrointestinal system or through the mouth, by swallowing into the gastrointestinal system or through the mouth, by swallowing into the gastrointestinal system or through the mouth, by swallowing into the gastrointestinal system or through the mouth, by swallowing into the gastrointestinal system or throu				
8         (delta-10 THC). This term also includes any synthetic cannabinoid derived from hemp and contained in a hemp-derived consumable product.           9         from hemp and contained in a hemp-derived consumable product.           10         (7)         Hemp-derived consumable product. A hemp product that is a finished good intended for human ingestion or inhalation that contains a delta-9 THC concentration of not more than three-tenths of one percent (0.3%) on a dry weight basis, but may contain concentrations of other hemp-derived cannabinoids, in excess of that amount. This term does not include hemp products intended for topical application, or seeds or seed derived ingredients that are generally recognized as safe by the United States Food and Drug Administration (FDA).           18         (8)         Hemp product. – As defined in G.S. 90-87.           19         (9)         Independent testing laboratory. – A laboratory that meets all of the following conditions:           21         a.         Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.           24         b.         Does not have a direct or indirect interest in the entity whose product is being tested.           25				
9       from hemp and contained in a hemp-derived consumable product.         10       (7)       Hemp-derived consumable product. — A hemp product that is a finished good intended for human ingestion or inhalation that contains a delta-9 THC concentration of not more than three-tenths of one percent (0.3%) on a dry weight basis, but may contain concentrations of other hemp-derived cannabinoids, in excess of that amount. This term does not include hemp products intended for topical application, or seeds or seed derived ingredients that are generally recognized as safe by the United States Food and Drug Administration (FDA).         18       (8)       Hemp product. — As defined in G.S. 90-87.         19       (9)       Independent testing laboratory. — A laboratory that meets all of the following conditions:         21       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         22       Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.       Does not have a direct or indirect interest in the entity whose product is being tested.         23       c.       Does not have a direct or any other jurisdiction.         24       b.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         23       using the high-performance chromatography (HPLC) testing method.         24       b.       Does not have a direct orindirect interest in the				
10       (7)       Hemp-derived consumable product A hemp product that is a finished good intended for human ingestion or inhalation that contains a delta-9 THC concentration of not more than three-tenths of one percent (0.3%) on a dry contain intended for topical application, or seeds or seed derived ingredients that are generally recognized as safe by the United States Food and Drug Administration (FDA).         18       (8)       Hemp product, - As defined in G.S. 90-87.         19       (9)       Independent testing laboratory A laboratory that meets all of the following conditions:         20       conditions:       a.         21       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         22       b.       Does not have a direct or indirect interest in the entity whose product is being tested.         23       (1301.13.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         24       b.       Does not have a chreact or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable product in this State or any other jurisdiction.         25       c.       Does not have a direct or indirect interest in a facility that cultivates, processes di consuming hemp through the mouth, by swallowing into the gastrointestinal system or through tissue absorption.         26       (10) <td></td> <td></td> <td></td> <td></td>				
11       intended for human ingestion or inhalation that contains a delta-9 THC         12       concentration of not more than three-tenths of one percent (0.3%) on a dry         13       weight basis, but may contain concentrations of other hemp-derived         14       cannabinoids, in excess of that amount. This term does not include hemp         15       products intended for topical application, or seeds or seed derived ingredients         16       that are generally recognized as safe by the United States Food and Drug         17       Administration (FDA).         18       (8)         19       (9)         10       Independent testing laboratory. – A laboratory that meets all of the following         20       conditions:         21       a.         21       a.         22       Enforcement Administration (DEA) in accordance with 21 C.F.R. §         23       1301.13.         24       b.       Does not have a direct or indirect interest in a facility that cultivates,         25       g.       Does not have a direct or any other jurisdiction.         26       c.       Does not have a compliance agreement with the ALE Division to conduct tetrahydrocannabinol concentration sampling and testing         26       d.       Has entered into a compliance agreement with the ALE Division to conduct tetrahydrocannabinol concen		(7)		
12       concentration of not more than three-tenths of one percent (0.3%) on a dry         13       weight basis, but may contain concentrations of other hemp-derived         14       cannabinoids, in excess of that amount. This term does not include hemp         15       products intended for topical application, or seeds or seed derived ingredients         16       that are generally recognized as safe by the United States Food and Drug         17       Administration (FDA),         18       (8)         19       (9)         10       Independent testing laboratory. — A laboratory that meets all of the following         20       conditions:         a.       Holds an ISO 17025 accreditation or is registered with the Drug         21       a.         22       Enforcement Administration (DEA) in accordance with 21 C.F.R. &         23       1301.13.         24       b.       Does not have a direct or indirect interest in the entity whose product         25       c.       Does not have a direct or indirect interest in a facility that cultivates,         26       c.       Does not have a direct or indirect interest in a facility that cultivates,         27       products in this State or any other jurisdiction.         28       products in this State or any other jurisdiction.         29       d. <td></td> <td><u></u></td> <td></td> <td></td>		<u></u>		
33       weight basis, but may contain concentrations of other hemp-derived cannabinoids, in excess of that amount. This term does not include hemp products intended for topical application, or seeds or seed derived ingredients that are generally recognized as safe by the United States Food and Drug Administration (FDA).         16       that are generally recognized as safe by the United States Food and Drug Administration (FDA).         17       Administration (FDA).         18       (8)         19       (9)         10       Independent testing laboratory. – A laboratory that meets all of the following conditions:         21       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         22       Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         24       b.       Does not have a direct or indirect interest in the entity whose product is being tested.         25       c.       Does not have a direct or any other jurisdiction.         26       c.       Does not have a compliance agreement with the ALE Division to conduct tetrahydrocannabinol concentration sampling and testing using the high-performance chromatography (HPLC) testing method.         27       Ingestion. – The process of consuming hemp through the mouth, by swallowing into the gastrointestinal system or through tissue absorption.         38       (12)       License. – Alicense issued in accordance with this Chapter. <td></td> <td></td> <td></td> <td></td>				
14       canabinoids, in excess of that amount. This term does not include hemp products intended for topical application, or seeds or seed derived ingredients that are generally recognized as safe by the United States Food and Drug Administration (FDA).         15       that are generally recognized as safe by the United States Food and Drug Administration (FDA).         18       (8)       Hemp product. – As defined in G.S. 90-87.         19       (9)       Independent testing laboratory. – A laboratory that meets all of the following conditions:         20       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         21       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         22       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         26       c.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         28       using the high-performance chromatography (HPLC) testing method, using the high-performance chromatography (HPLC) testing method.         30       using the high-performance chromatography (HPLC) testing method.         31       Indagesture. – To compound, blend, extract, infuse, cook			•	· · · · · · · · · · · · · · · · · · ·
15       products intended for topical application, or seeds or seed derived ingredients that are generally recognized as safe by the United States Food and Drug Administration (FDA).         16       that are generally recognized as safe by the United States Food and Drug Administration (FDA).         17       Administration (FDA).         18       (8)       Hemp product. — As defined in G.S. 90-87.         19       (9)       Independent testing laboratory. — A laboratory that meets all of the following conditions:         20       conditions:       a.         21       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. §         22       I301.13.       b.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         23       (1301.13)       b.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         24       b.       Ingestion. — The process of consuming hemp through the mouth, by swallowing into the gastrointestinal system or through the mouth, by swallowing into the gastrointestinal system or through the mouth, by swallowing into the gastrointestinal system or through the mouth, by swallowing into the gastrointestinal system or through the mouth, by swallowing into the gastrointestinal system or through the m			· · ·	-
16       that are generally recognized as safe by the United States Food and Drug Administration (PDA).         17       Administration (PDA).         18       (8)       Hemp product. – As defined in G.S. 90-87.         19       (9)       Independent testing laboratory. – A laboratory that meets all of the following conditions:         20       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         24       b.       Does not have a direct or indirect interest in the entity whose product is being tested.         25       c.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         26       d.       Has entered into a compliance agreement with the ALE Division to conduct tertahydrocannabinol concentration sampling and testing using the high-performance chromatography (HPLC) testing method.         27       using the high-performance chromatography (HPLC) testing method.         28       (10)       Ingestion. – The process of consuming hemp through the mouth, by swallowing into the gastrointestinal system or through tissue absorption.         28       through the mouth or nasal passages.         29       (11)       Inhalatorue. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable p				•
17       Administration (FDA).         18       (8)       Hemp product As defined in G.S. 90-87.         19       (9)       Independent testing laboratory A laboratory that meets all of the following conditions:         20       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         21       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         23       1301.13.       b.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         24       b.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         26       c.       Does not have a direct or indirect interest in a sampling and testing using the high-performance chromatography (HPLC) testing method.         27       swallowing into the gastrointestinal system or through the mouth, by swallowing into the gastrointestinal system or through the mouth, by swallowing into the gastrointestinal system or through the mouth, by swallowing into the gastrointestinal system or through the mouth or nasal passages.         26       (10)       Ingestion. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.				-
18       (8)       Hemp product. — As defined in G.S. 90-87.         19       (9)       Independent testing laboratory. — A laboratory that meets all of the following conditions:         20       conditions:       Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         24       b.       Does not have a direct or indirect interest in the entity whose product is being tested.         25       c.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         28       modulate into a compliance agreement with the ALE Division to conduct tetrahydrocannabinol concentration sampling and testing using the high-performance chromatography (HPLC) testing method.         29       d.       Has entered in a gassages.         31       Ungestion. — The process of consuming hemp into the respiratory system through the mouth or nasal passages.         36       (12)       License. — A license issued in accordance with this Chapter.         37       (13)       Manufacture. — To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.         36       (12)       License. — Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.         37       (13)				tes 1000 and Drug
19       (9)       Independent testing laboratory. – A laboratory that meets all of the following conditions:         20       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         24       b.       Does not have a direct or indirect interest in the entity whose product is being tested.         26       c.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         28       group conduct tetrahydrocannabinol concentration sampling and testing using the high-performance chromatography (HPLC) testing method.         29       (10)       Ingestion. – The process of consuming hemp through the mouth, by swallowing into the gastrointestinal system or through tissue absorption.         34       (11)       Inhalation. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.         35       through the mouth or anal passages.         36       (12)       License issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived canabinoid to make, prepare, or package hemp-derived consumable products.         39       hemp-derived consumable product.       14         41       Manufacture. – Any person or entity that engages in the process o		(8)		
20       conditions:         a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         21       a.         22       Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         23       1301.13.         24       b.       Does not have a direct or indirect interest in the entity whose product is being tested.         25       c.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         28       processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         29       d.       Has entered into a compliance agreement with the ALE Division to conduct tetrahydrocannabinol concentration sampling and testing using the high-performance chromatography (HPLC) testing method.         30       using the nigh-performance chromatography (HPLC) testing method.         31       Ingestion. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacturer. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.         40			• •	all of the following
21       a.       Holds an ISO 17025 accreditation or is registered with the Drug Enforcement Administration (DEA) in accordance with 21 C.F.R. § 1301.13.         23       1301.13.         24       b.       Does not have a direct or indirect interest in the entity whose product is being tested.         26       c.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         28       products in this State or any other jurisdiction.         29       d.         4.       Has entered into a compliance agreement with the ALE Division to conduct tetrahydrocannabinol concentration sampling and testing using the high-performance chromatography (HPLC) testing method.         30       Ingestion. – The process of consuming hemp through the mouth, by swallowing into the gastrointestinal system or through tissue absorption.         34       (11)       Inhalation. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.         40       (14)       Manufacture. – Any person or entity that engages in the process of manufacturing, preparing, or packaging of hemp-derived consu		<u>())</u>		an of the following
22       Enforcement Administration (DEA) in accordance with 21 C.F.R. §         23       1301.13.         24       b. Does not have a direct or indirect interest in the entity whose product is being tested.         25       c. Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable         26       c. Does not have a direct or any other jurisdiction.         27       processes, distributes, dispenses, or sells hemp-derived consumable         28       products in this State or any other jurisdiction.         29       d. Has entered into a compliance agreement with the ALE Division to         30       conduct tetrahydrocannabinol concentration sampling and testing         31       using the high-performance chromatography (HPLC) testing method.         32       (10)       Ingestion. – The process of consuming hemp through the mouth, by         33       swallowing into the gastrointestinal system or through tissue absorption.         34       (11)       Inhalation. – The process of consuming hemp into the respiratory system         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise         38       manufacture. – Any person or entity that engages in the process of         40				red with the Drug
1301.13.         131         131         131         131         131         131         131         131         131         131         131         131         132         133         133         134         135         136         131         132         133         133         134         135         135         136         131				
24       b.       Does not have a direct or indirect interest in the entity whose product is being tested.         25        Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         28        Has entered into a compliance agreement with the ALE Division to conduct tetrahydrocannabinol concentration sampling and testing using the high-performance chromatography (HPLC) testing method.         30        Ingestion. – The process of consuming hemp through the mouth, by swallowing into the gastrointestinal system or through tissue absorption.         34       (11)       Inhalation. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.         40       (14)       Manufacturer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.         44       14a)       Producer. – Any person or entity that engages in the product to the ultimate consume of the product, including an online seller.         45       15)       Seller. – Any person or entity that engages in the manufactu				<u>e witti 21 C.P.R. g</u>
25       is being tested.         26       c. Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         28       products in this State or any other jurisdiction.         29       d. Has entered into a compliance agreement with the ALE Division to conduct tetrahydrocannabinol concentration sampling and testing using the high-performance chromatography (HPLC) testing method.         30       using the high-performance chromatography (HPLC) testing method.         31       using the high-performance chromatography (HPLC) testing method.         32       (10)       Ingestion. – The process of consuming hemp through the mouth, by swallowing into the gastrointestinal system or through tissue absorption.         33       (11)       Inhalation. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.         40       (14)       Manufacture. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.         43       (14a)       Producer. – Any person or entity that engages				tity whose product
26       c.       Does not have a direct or indirect interest in a facility that cultivates, processes, distributes, dispenses, or sells hemp-derived consumable products in this State or any other jurisdiction.         27       d.       Has entered into a compliance agreement with the ALE Division to conduct tetrahydrocannabinol concentration sampling and testing using the high-performance chromatography (HPLC) testing method.         28       using the high-performance chromatography (HPLC) testing method.         30       using the high-performance chromatography (HPLC) testing method.         31       using the mouth or process of consuming hemp through the mouth, by swallowing into the gastrointestinal system or through tissue absorption.         34       (11)       Inhalation. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.         35       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.         40       (14)       Manufacture. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.         44       harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.         45       Seller. – Any person or entity that engages in the process of farming an				nity whose product
27       processes, distributes, dispenses, or sells hemp-derived consumable         28       products in this State or any other jurisdiction.         29       d.       Has entered into a compliance agreement with the ALE Division to         30       conduct tetrahydrocannabinol concentration sampling and testing         31       using the high-performance chromatography (HPLC) testing method.         32       (10)       Ingestion. – The process of consuming hemp through the mouth, by         33       swallowing into the gastrointestinal system or through tissue absorption.         34       (11)       Inhalation. – The process of consuming hemp into the respiratory system         35       through the mouth or nasal passages.         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise         38       manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package         39       hemp-derived consumable products.         40       (14)       Manufacturer. – Any person or entity that engages in the process of farming and         41       producer. – Any person or entity that engages in the process of farming and         42       products.         43       (14a)         Producer. – Any person or entity that en				ility that aultivates
28       products in this State or any other jurisdiction.         29       d. Has entered into a compliance agreement with the ALE Division to         30       conduct tetrahydrocannabinol concentration sampling and testing         31       using the high-performance chromatography (HPLC) testing method.         32       (10)       Ingestion. – The process of consuming hemp through the mouth, by         33       swallowing into the gastrointestinal system or through tissue absorption.         34       (11)       Inhalation. – The process of consuming hemp into the respiratory system         35       through the mouth or nasal passages.         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise         38       manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package         39       hemp-derived consumable products.         40       (14)       Manufacturer. – Any person or entity that engages in the process of farming and         41       harvesting hemp that is intended to be used in the manufacture of a         42       products.         43       (14a)         Producer. – Any person who sells a hemp-derived consumable product to the         44       harvesting hemp that is intended to be used in the manufa				-
29       d. Has entered into a compliance agreement with the ALE Division to         30       conduct tetrahydrocannabinol concentration sampling and testing         31       using the high-performance chromatography (HPLC) testing method.         32       (10)       Ingestion. – The process of consuming hemp through the mouth, by         33       swallowing into the gastrointestinal system or through tissue absorption.         34       (11)       Inhalation. – The process of consuming hemp into the respiratory system         35       through the mouth or nasal passages.         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise         38       manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package         39       hemp-derived consumable products.         40       (14)       Manufacturer. – Any person or entity that engages in the process of farming and         41       manufacture or packaging of hemp-derived consumable       produces.         43       (14a)       Producer. – Any person or entity that engages in the process of farming and         44       harvesting hemp that is intended to be used in the manufacture of a         45       hemp-derived consumable product.         46       (15)       Sell				enveu consumable
30       conduct tetrahydrocannabinol concentration sampling and testing using the high-performance chromatography (HPLC) testing method.         31       using the high-performance chromatography (HPLC) testing method.         32       (10)       Ingestion. – The process of consuming hemp through the mouth, by swallowing into the gastrointestinal system or through tissue absorption.         34       (11)       Inhalation. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.         40       (14)       Manufacturer. – Any person or entity that engages in the process of manufacturing, preparing, or packaging of hemp-derived consumable products.         43       (14a)       Producer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.         46       (15)       Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.         48       (16)       Serving. – A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.         50       "§ 18D-101. Sales restrictions on hemp-derived consumable produ			· · ·	ALE Division to
31       using the high-performance chromatography (HPLC) testing method.         32       (10)       Ingestion. – The process of consuming hemp through the mouth, by swallowing into the gastrointestinal system or through tissue absorption.         33       (11)       Inhalation. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.         40       (14)       Manufacturer. – Any person or entity that engages in the process of manufacturing, preparing, or packaging of hemp-derived consumable products.         43       (14a)       Producer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.         44       harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.         45       Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.         48       (16)       Serving. – A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.         50       "§ 18D-101. Sales restrictions on hemp-derived consumable products.				
<ul> <li>(10) Ingestion. – The process of consuming hemp through the mouth, by swallowing into the gastrointestinal system or through tissue absorption.</li> <li>(11) Inhalation. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.</li> <li>(12) License. – A license issued in accordance with this Chapter.</li> <li>(13) Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.</li> <li>(14) Manufacturer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.</li> <li>(15) Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.</li> <li>(16) Serving. – A quantity of a hemp-derived consumable products.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>				
33       swallowing into the gastrointestinal system or through tissue absorption.         34       (11)       Inhalation. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.         39       hemp-derived consumable products.         40       (14)       Manufacturer. – Any person or entity that engages in the process of manufacturing, preparing, or packaging of hemp-derived consumable products.         41       manufacture. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.         42       (14a)       Producer. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.         43       (15)       Seller. – Any uparison who sells a hemp-derived consumable product reasonably suitable for a person's use in a single day.         49       "§ 18D-101.       Sales restrictions on hemp-derived consumable products.		(10)		
<ul> <li>(11) Inhalation. – The process of consuming hemp into the respiratory system through the mouth or nasal passages.</li> <li>(12) License. – A license issued in accordance with this Chapter.</li> <li>(13) Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.</li> <li>(14) Manufacturer. – Any person or entity that engages in the process of manufacturing, preparing, or packaging of hemp-derived consumable products.</li> <li>(14a) Producer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.</li> <li>(15) Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.</li> <li>(16) Serving. – A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>		(10)		
35       through the mouth or nasal passages.         36       (12)       License. – A license issued in accordance with this Chapter.         37       (13)       Manufacture. – To compound, blend, extract, infuse, cook, or otherwise         38       manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package         39       hemp-derived consumable products.         40       (14)       Manufacturer. – Any person or entity that engages in the process of         41       manufacturing, preparing, or packaging of hemp-derived consumable         42       products.         43       (14a)         44       hemp-derived consumable product.         45       hemp-derived consumable product.         46       (15)       Seller. – Any person or entity that engages in the manufacture of a hemp-derived consumable product.         46       (15)       Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.         47       ultimate consumer of the product, including an online seller.         48       (16)       Serving. – A quantity of a hemp-derived consumable products.         50       "§ 18D-101. Sales restrictions on hemp-derived consumable products.		(11)		•
<ul> <li>(12) License. – A license issued in accordance with this Chapter.</li> <li>(13) Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.</li> <li>(14) Manufacturer. – Any person or entity that engages in the process of manufacturing, preparing, or packaging of hemp-derived consumable products.</li> <li>(14a) Producer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.</li> <li>(15) Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.</li> <li>(16) Serving. – A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>		<u>(11)</u>	• • •	respiratory system
<ul> <li>(13) Manufacture. – To compound, blend, extract, infuse, cook, or otherwise manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.</li> <li>(14) Manufacturer. – Any person or entity that engages in the process of manufacturing, preparing, or packaging of hemp-derived consumable products.</li> <li>(14a) Producer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.</li> <li>(15) Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.</li> <li>(16) Serving. – A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>		(10)		
<ul> <li>manipulate hemp or a hemp-derived cannabinoid to make, prepare, or package hemp-derived consumable products.</li> <li>(14) Manufacturer. – Any person or entity that engages in the process of manufacturing, preparing, or packaging of hemp-derived consumable products.</li> <li>(14a) Producer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.</li> <li>(15) Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.</li> <li>(16) Serving. – A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>			=	
<ul> <li>hemp-derived consumable products.</li> <li>(14) Manufacturer. – Any person or entity that engages in the process of manufacturing, preparing, or packaging of hemp-derived consumable products.</li> <li>(14a) Producer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.</li> <li>(15) Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.</li> <li>(16) Serving. – A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>		<u>(13)</u>		
<ul> <li>(14) Manufacturer. – Any person or entity that engages in the process of manufacturing, preparing, or packaging of hemp-derived consumable products.</li> <li>(14a) Producer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.</li> <li>(15) Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.</li> <li>(16) Serving. – A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>				prepare, or package
<ul> <li>manufacturing, preparing, or packaging of hemp-derived consumable</li> <li>products.</li> <li>(14a) Producer. – Any person or entity that engages in the process of farming and</li> <li>harvesting hemp that is intended to be used in the manufacture of a</li> <li>hemp-derived consumable product.</li> <li>(15) Seller. – Any person who sells a hemp-derived consumable product to the</li> <li>ultimate consumer of the product, including an online seller.</li> <li>(16) Serving. – A quantity of a hemp-derived consumable product reasonably</li> <li>suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>				
<ul> <li>42 products.</li> <li>43 (14a) Producer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.</li> <li>46 (15) Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.</li> <li>48 (16) Serving. – A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.</li> <li>50 "§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>		<u>(14)</u>		-
<ul> <li>(14a) Producer. – Any person or entity that engages in the process of farming and harvesting hemp that is intended to be used in the manufacture of a hemp-derived consumable product.</li> <li>(15) Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.</li> <li>(16) Serving. – A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>				erived consumable
<ul> <li>harvesting hemp that is intended to be used in the manufacture of a</li> <li>hemp-derived consumable product.</li> <li>(15) Seller. – Any person who sells a hemp-derived consumable product to the</li> <li>ultimate consumer of the product, including an online seller.</li> <li>(16) Serving. – A quantity of a hemp-derived consumable product reasonably</li> <li>suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>				
<ul> <li>hemp-derived consumable product.</li> <li>(15) Seller. – Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.</li> <li>(16) Serving. – A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>		<u>(14a)</u>		-
<ul> <li>(15) Seller Any person who sells a hemp-derived consumable product to the ultimate consumer of the product, including an online seller.</li> <li>(16) Serving A quantity of a hemp-derived consumable product reasonably suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>				manufacture of a
<ul> <li>47 <u>ultimate consumer of the product, including an online seller.</u></li> <li>48 (16) <u>Serving. – A quantity of a hemp-derived consumable product reasonably</u></li> <li>49 <u>suitable for a person's use in a single day.</u></li> <li>50 "<u>§ 18D-101. Sales restrictions on hemp-derived consumable products.</u></li> </ul>				
<ul> <li>(16) Serving A quantity of a hemp-derived consumable product reasonably</li> <li>suitable for a person's use in a single day.</li> <li>"§ 18D-101. Sales restrictions on hemp-derived consumable products.</li> </ul>		<u>(15)</u>	• •	±
<ul> <li>49 <u>suitable for a person's use in a single day.</u></li> <li>50 "<u>§ 18D-101. Sales restrictions on hemp-derived consumable products.</u></li> </ul>				
50 " <u>§ 18D-101. Sales restrictions on hemp-derived consumable products.</u>		<u>(16)</u>		product reasonably
51 (a) <u>Restrictions. – No person shall do any of the following:</u>				
	51	(a) <u>Restric</u>	ctions. – No person shall do any of the following:	

	General Assen	mbly Of North Carolina	Session 2023
1	(1)	Knowingly, or having reason to know, sell a hemp-de	rived consumable
2		product to a person who is under 21 years of age.	
3	(2)	Knowingly, or having reason to know, distribute samples	of hemp-derived
4		consumable products in or on a public street, sidewalk, or p	<u>vark.</u>
5	<u>(3)</u>	Engage in the business of selling a hemp-derived consumab	le product without
6		a valid license issued in accordance with this Chapter.	-
7	<u>(4)</u>	Knowingly, or having reason to know, sell at retail	a hemp-derived
8		consumable product that has a concentration of more than t	hree-tenths of one
9		percent (0.3%) on a dry weight basis total comb	oined of delta-9
10		tetrahydrocannabinol.	
11	<u>(5)</u>	Knowingly, or having reason to know, sell a hemp-dem	rived consumable
12		product that is not contained in an exit package.	
13	<u>(6)</u>	Knowingly, or having reason to know, sell at retail or on a	n internet website.
14		offering delivery in this State, a hemp-derived consumable	product that is not
15		in compliance with G.S. 18D-105.	
16	<u>(7)</u>	Knowingly, or having reason to know, sell at retail hemp fl	ower or a product
17		containing hemp flower that is not accompanied by a cert	ificate of analysis
18		issued within the previous six-month period demonstrati	ng that the hemp
19		flower or product containing hemp flower has a concentration	on of no more than
20		three-tenths of one percent (0.3%) on a dry weight	basis of delta-9
21		tetrahydrocannabinol.	
22	<u>(b)</u> <u>Civ</u>	vil Penalties Violation of this section shall have the following	
23	<u>(1)</u>		enalty of no more
24		than five hundred dollars (\$500.00).	
25	<u>(2)</u>		
26		civil penalty of no more than seven hundred fifty dollars (\$	
27	<u>(3)</u>		
28		shall impose a civil penalty of no more than one thousand do	ollars (\$1,000) and
29		suspend the seller's license for one year.	
30	<u>(4)</u>		
31		the Department shall impose a civil penalty of no more t	<u>han two thousand</u>
32		dollars (\$2,000) and revoke the seller's license.	1 1
33		mpromise. – In any case in which the Department is entitled to	*
34		ise, the Department may accept from the seller an offer in con	
35		more than three thousand dollars (\$3,000). The Department m	
36	-	r revoke a license, but not both. The Department may accept a	a compromise and
37		cense in the same case.	
38		sting Fee. $-$ In any case in which the Department imposes a point of this section for a violation of subdivision (4) of subsection	
39 40		of this section, for a violation of subdivision (4) of subsection	
40 41		also pay to the Department the actual costs paid by the ALE D	
41 42	÷	s resulting in the violation. Any fee collected pursuant to this s	ubsection shall be
43		<u>e ALE Division.</u> fenses. – It is a defense to a violation of subdivision (1) of sub	eaction (a) of this
+3 44		seller does any of the following:	section (a) of this
45	(1)	· •	cial identification
46	<u>(1)</u>	card issued under G.S. 20-37.7 or issued by the state agency	
47		authorized to issue similar official state special identificat	•
+7 48		state, a tribal enrollment card issued by a State or federally	
49		Tribe, a military identification card, or a passport showing t	
49 50		to be at least the required age for purchase and bearing a ph	
50 51		of the person named on the card reasonably describing the	• •
51		or the person named on the card reasonably describing the	<u>purchaser.</u>

General Assen	nbly Of North Carolina	Session 2023
<u>(2)</u>	Produces evidence of other facts that reasonably in	dicated at the time of sale
	that the purchaser was at least the required age.	
<u>(3)</u>	Shows that at the time of purchase, the purcha	aser utilized a biometric
	identification system that demonstrated (i) the pure	
	the required age for the purchase and (ii) the p	
	registered with the seller or seller's agent a d	
	identification card issued under G.S. 20-37.7 or issu	-
	any other state authorized to issue similar official s	
	<u>cards for that state, a military identification card, of</u>	-
	purchaser's date of birth and bearing a physical of	
	named on the document.	description of the person
(f) Pro	<u>seeds of Civil Penalty. – The clear proceeds of any civ</u>	vil penalty imposed under
	cluding any penalty received as an offer in compromise	
	nd Forfeiture Fund in accordance with G.S. 115C-457.2	
	eiture. – Any product sold in violation of subdivision (4	
	subject to forfeiture pursuant to the procedures set fort	
	ninal Penalty. – Any person against whom a civil pena	
	odivision (3) of subsection (a) of this section who come	
	of subsection (a) of this section is guilty of a Class A1 r	• •
	third or subsequent violation of subdivision (3) of sub	section (a) of this section
is guilty of a C		
	Sales and transfer restrictions on a producer.	
	triction. – A producer shall not knowingly sell or in an	• • • •
-	ssed or prepared with the intent to be used in a hemp-de	
	r entity other than a manufacturer licensed pursuant to	<b>•</b>
	<u>l Penalties. – Violation of this section shall have the fo</u>	
<u>(1)</u>	For the first violation, the Department may impose	a civil penalty of no more
	than five hundred dollars (\$500.00).	· · · ·
<u>(2)</u>	For the second violation within three years, the D	* * *
	civil penalty of no more than seven hundred fifty do	
<u>(3)</u>	For the third violation within three years of the first	-
	shall impose a civil penalty of no more than one the	
<u>(4)</u>	For a fourth or subsequent violation within three y	
	the Department shall impose a civil penalty of no	more than two thousand
	<u>dollars (\$2,000).</u>	•1 1. • 1 1
	<u>ceeds of Civil Penalty. – The clear proceeds of any civ</u>	
	all be remitted to the Civil Penalty and Forfeiture I	Fund in accordance with
<u>G.S. 115C-457</u>		1. 1. 1. 1. 1.0
	ninal Penalty. – Any person against whom a civil pena	
	s section who commits a second violation of this section	
	Any person who commits a third or subsequent violation	on of this section is guilty
of a Class H fe		
	licability of this Section Nothing in this sectio	
	oducer from selling or transferring hemp that is intende	ed to be used in any lawful
*	han those regulated by this Chapter.	
	Offenses involving the purchase, attempted purchase,	
	p-derived consumable products by a person under	
	unlawful for any person to give a hemp-derived consu	imable product to anyone
less than 21 year		
	unlawful for a person less than 21 years old to posses	s, purchase, or attempt to
purchase a hem	p-derived consumable product.	

	General A	Assem	bly Of North Carolina	Session 2023
l	<u>(c)</u>	<u>It is </u>	inlawful for any person to enter or attempt to enter a place	where hemp-derived
2	<u>consumab</u>	le pro	ducts are sold or consumed, or to obtain or attempt to o	btain hemp-derived
;	<u>consumab</u>	le pro	ducts, or to obtain or attempt to obtain permission to pur	chase hemp-derived
		-	ducts, in violation of subsection (b) of this section, by using	_
	any of the	-		• •
		(1)	A fraudulent or altered drivers license.	
		(2)	A fraudulent or altered identification document other than	n a drivers license.
		(3)	A drivers license issued to another person.	
		(4)	An identification document other than a drivers licens	e issued to another
		<u> </u>	person.	
		(5)	Any other form or means of identification that indicates or	r symbolizes that the
		<u>(e)</u>	person is not prohibited from purchasing or possessi	
			consumable product under this section.	ng u nomp donvou
	(d)	It is 1	unlawful for any person to permit the use of the person's du	ivers license or any
			entification of any kind issued or given to the person by ar	
			upts to violate subsection (b) of this section.	<u>ry other person who</u>
	<u>(e)</u>		Ities. –	
	<u>(c)</u>	$\frac{1 \text{ cma}}{(1)}$	Any person less than 21 years old who violates this sectio	n is guilty of a Class
		<u>(1)</u>	<u>2 misdemeanor.</u>	<u>Il 18 guilty 01 a Class</u>
		(2)		in milty of a Class
		<u>(2)</u>	Any person at least 21 years old who violates this section	<u>I is guilty of a Class</u>
		(2)	<u>1 misdemeanor.</u>	ished as movided in
		<u>(3)</u>	Aiding or abetting a violation of this section shall be pun which divisions (1) and (2) of this subsection, and all other	=
			subdivisions (1) and (2) of this subsection, and all other	er provisions of this
		NT (1	section shall apply to that offense.	. , <b>.</b>
	<u>(f)</u> .		ing in this section prohibits an underage person from sell	
			b-derived consumable products in the course of employmen	
			that purpose is lawful under applicable youth employment	
	" <u>§ 18D-1</u>		Offenses involving the manufacture and distribution	of hemp-derived
			umable products.	
	<u>(a)</u>	-	nses. – It is unlawful for a manufacturer or distributor to do a	
		<u>(1)</u>	Knowingly, or having reason to know, distribute sample	-
			consumable product in or on a public street, sidewalk, or	
		<u>(2)</u>	Engage in the business of manufacturing or distributi	-
			consumable product without a valid license issued in a	ccordance with this
			Chapter.	
		<u>(3)</u>	Knowingly, or having reason to know, manufactu	
			hemp-derived consumable product that has a concentr	
			three-tenths of one percent (0.3%) on a dry weight basi	s total combined of
			delta-9 tetrahydrocannabinol.	
	<u>(b)</u>		inal Penalties A violation of this section is a Class A1 mi	
	<u>(c)</u>		Penalties In addition to any criminal punishment author	-
	<u>for any vi</u>	olatior	n of this section the Department shall take one or more of the	ne following actions
	against the	e licen	see:	
		<u>(1)</u>	Suspend the licensee's license for a specified period of t	ime not longer than
			three years.	
		(2)	Revoke the licensee's license.	
		(3)	Impose conditions on the operating hours of the licensee'	s business.
		(4)	Impose civil penalties as follows:	
			<u>a.</u> For a first violation, impose a civil penalty of	no more than one
			thousand dollars (\$1,000).	

	General Assemb	ly Of N	lorth Carolina	Session 2023
1		<u>b.</u>	For a second violation within three y	ears, impose a civil penalty of no
2			more than five thousand dollars (\$5,0	000).
3		<u>c.</u>	For a third violation within three year	urs of the first violation, impose a
4			civil penalty of no more than seven	n thousand five hundred dollars
5			<u>(\$7,500).</u>	
6	<u>(d)</u> <u>Comp</u>	romise.	- In any case in which the Department	nt is entitled to suspend or revoke
7	a manufacturer's	or distr	ibutor's license, the Department may	accept from the manufacturer or
8	distributor an off	fer in c	ompromise to pay a penalty of not n	nore than eight thousand dollars
9	<u>(\$8,000). The Dep</u>	partmer	nt may either accept a compromise or re	evoke a license, but not both. The
10		-	a compromise and suspend the license	
11			<ul> <li>In any case in which the Department</li> </ul>	
12			tion, for a violation of subdivision (3)	
13			ributor shall also pay to the Department	<b>.</b> .
14	· · ·		Division for testing of the samples re	
15	-		subsection shall be remitted to the AI	
16			Civil Penalty. – The clear proceeds of	
17		_	ny penalty received as an offer in com	
18			ure Fund in accordance with G.S. 115	
19			is a defense to a violation of subdivi	sion (3) of subsection (a) of this
20			er does all of the following:	
21 22	<u>(1)</u>		s all hemp-derived consumable products	ucts from the same batch as the
22 23	( <b>2</b> )		ct on which the violation is based.	anondant testing laboratory. The
23 24	<u>(2)</u>		amples of the batch tested by an inde e size required for testing pursuant to the	
24 25			mber of units required pursuant to G.S	
23 26			tch at production, regardless of the nu	
20 27		recalle		inder of units that are able to be
28	<u>(3)</u>		les certified results from the independent	lent testing laboratory indicating
29			he sample tested does not contain	
30			tenths of one percent $(0.3\%)$ on a dry	
31			9 tetrahydrocannabinol.	
32	(h) Forfei		Any product sold in violation of subdiv	vision (3) of subsection (a) of this
33	section shall be su	ubject t	o forfeiture pursuant to the procedures	set forth in G.S. 18D-401.
34	" <u>§ 18D-104. Tes</u>	ting pr	ior to distribution.	
35	<u>(a)</u> <u>Requi</u>	rement.	- The manufacturer shall have a he	mp-derived consumable product
36	tested prior to di	stributi	on to a distributor or before distributi	ng the product to a seller. If the
37			le product is packaged in a manner t	
38			when delivered to the distributor and t	•
39			is not required to test the hemp-deri	•
40			le product is not packaged in a manner	-
41		-	t when delivered to the distributor of	<b>.</b>
42			shall have the hemp-derived cons	
43		-	shall determine the presence and amou	
44			s section. No product that contains n	
45		substa	nce in subsection (b) of this section sl	hall be distributed or sold in this
46 47	State.	maaa T	astadi Limitationa Uamp dariwad aa	noumable meduate shall be tested
47 48			ested; Limitations. – Hemp-derived con amount of the following substances a	
48 49	indicated:	u allu	amount of the following substances a	ng shan not exceed the amounts
49 50	<u>(1)</u>	Canna	binoids, not to exceed a concentratio	on of three-tenths of one percent
51	<u>\1)</u>		) total combined of delta-9 tetrahydroc	
~ 1		<u></u> /0	, total comonica of actu / totaliyaloa	······································

	General Assemb	bly Of North Carolina Session 20	023
1	(2)	2,3-butanedione (Diacetyl).	
2	$\overline{(3)}$	Abamectin, not to exceed 300 parts per billion for ingestion or 100 parts	per
3		billion for inhalation.	•
4	<u>(4)</u>	Acephate, not to exceed 3,000 parts per billion for ingestion or 100 parts	per
5	<u></u>	billion for inhalation.	±
6	<u>(5)</u>	Acequinocyl, not to exceed 2,000 parts per billion for ingestion or 100 parts	arts
7		per billion for inhalation.	
8	<u>(6)</u>	Acetamiprid, not to exceed 3,000 parts per billion for ingestion or 100 pa	<u>arts</u>
9 10	(7)	per billion for inhalation.	
10	$\frac{(7)}{(8)}$	Aldicarb, not to exceed 100 parts per billion for ingestion or inhalation.	orta
11	<u>(8)</u>	Azoxystrobin, not to exceed 3,000 parts per billion for ingestion or 100 pa	arts
12	( <b>0</b> )	per billion for inhalation. Biferenzeta not to avoand 2,000 ports per billion for ingestion or 100 ports.	
13 14	<u>(9)</u>	Bifenazate, not to exceed 3,000 parts per billion for ingestion or 100 parts	per
14 15	(10)	billion for inhalation. Biferthrin, not to exceed 500 parts per hillion for ingestion or 100 parts.	
15 16	<u>(10)</u>	Bifenthrin, not to exceed 500 parts per billion for ingestion or 100 parts points billion for inhalation.	per
10	(11)	Boscalid, not to exceed 3,000 parts per billion for ingestion or 100 parts	nor
17	<u>(11)</u>	billion for inhalation.	per
18	(12)	Captan, not to exceed 3,000 parts per billion for ingestion or 700 parts	nor
20	<u>(12)</u>	billion for inhalation.	per
20	<u>(13)</u>	Carbaryl, not to exceed 500 parts per billion for ingestion or 500 parts	ner
21	<u>(13)</u>	billion for inhalation.	per
22	(14)	Carbofuran, not to exceed 100 parts per billion for ingestion or inhalation.	
23 24	(14) (15)	<u>Chlorantraniliprole, not to exceed 3,000 parts per billion for ingestion or 1,0</u>	
25	<u>(15)</u>	parts per billion for inhalation.	<u> </u>
26	(16)	Chlordane, not to exceed 100 parts per billion for ingestion or inhalation.	
27	(17)	Chlorfenapyr, not to exceed 100 parts per billion for ingestion or inhalation	m.
28	$\frac{(17)}{(18)}$	Chlormequat chloride, not to exceed 3,000 parts per billion for ingestion	
29	<u>(10)</u>	1,000 parts per billion for inhalation.	
30	(19)	Chlorpyrifos, not to exceed 100 parts per billion for ingestion or inhalation	n.
31	(20)	Clofentezine, not to exceed 500 parts per billion for ingestion or 200 parts	
32	<u>,                                     </u>	billion for inhalation.	±
33	(21)	Coumaphos, not to exceed 100 parts per billion for ingestion or inhalation	
34	$\overline{(22)}$	Cyfluthrin, not to exceed 1,000 parts per billion for ingestion or 500 parts	per
35		billion for inhalation.	-
36	<u>(23)</u>	Cypermethrin, not to exceed 1,000 parts per billion for ingestion or 500 pa	arts_
37		per billion for inhalation.	
38	<u>(24)</u>	Daminozide, not to exceed 100 parts per billion for ingestion or inhalation	<u>ı.</u>
39	<u>(25)</u>	DDVP (Dichlorvos), not to exceed 100 parts per billion for ingestion	or
40		inhalation.	
41	<u>(26)</u>	Diazinon, not to exceed 200 parts per billion for ingestion or 100 parts	per
42		billion for inhalation.	
43	<u>(27)</u>	Dimethoate, not to exceed 100 parts per billion for ingestion or inhalation.	<u>.</u>
44	<u>(28)</u>	Dimethomorph, not to exceed 3,000 parts per billion for ingestion or 200 pa	arts_
45		per billion for inhalation.	
46	<u>(29)</u>	Ethoprop(hos), not to exceed 100 parts per billion for ingestion or inhalation	on.
47	(30)	Etofenprox, not to exceed 100 parts per billion for ingestion or inhalation.	
48	<u>(31)</u>	Etoxazole, not to exceed 1,500 parts per billion for ingestion or 100 parts	per
49		billion for inhalation.	
50	<u>(32)</u>	Fenhexamid, not to exceed 3,000 parts per billion for ingestion or 100 pa	arts_
51		per billion for inhalation.	

Gener	al Assemb	oly Of North Carolina	Session 2023
	(33)	Fenoxycarb, not to exceed 100 parts per billion for inge	stion or inhalation.
	$\frac{(33)}{(34)}$	Fenpyroximate, not to exceed 2,000 parts per billion for	
	<u>(31)</u>	per billion for inhalation.	ingestion of 100 pure
	(35)	Fipronil, not to exceed 100 parts per billion for ingestio	n or inhalation
	<u>(36)</u>	Flonicamid, not to exceed 2,000 parts per billion for ingestion	
	<u>(30)</u>	billion for inhalation.	estion of 100 parts per
	(27)		nanction on 100 nont
	<u>(37)</u>	Fludioxonil, not to exceed 3,000 parts per billion for i	ngestion or 100 parts
	(20)	per billion for inhalation.	. 100 .
	<u>(38)</u>	Hexythiazox, not to exceed 2,000 parts per billion for	ingestion or 100 parts
	(20)	per billion for inhalation.	
	<u>(39)</u>	Imazalil, not to exceed 100 parts per billion for ingestio	
	<u>(40)</u>	Imidacloprid, not to exceed 3,000 parts per billion for	ingestion or 400 parts
		per billion for inhalation.	
	<u>(41)</u>	Kresoxim-methyl, not to exceed 1,000 parts per billion	<u>n for ingestion or 100</u>
		parts per billion for inhalation.	
	(42)	Malathion, not to exceed 2,000 parts per billion for inge	estion or 200 parts per
		billion for inhalation.	
	<u>(43)</u>	Metalaxyl, not to exceed 3,000 parts per billion for inge	estion or 100 parts per
		billion for inhalation.	
	<u>(44)</u>	Methiocarb, not to exceed 100 parts per billion for inge	stion or inhalation.
	(45)	Methomyl, not to exceed 100 parts per billion for ingest	tion or inhalation.
	(46)	Methyl parathion, not to exceed 100 parts per bill	ion for ingestion of
		inhalation.	-
	(47)	Mevinphos, not to exceed 100 parts per billion for inges	stion or inhalation.
	(48)	Myclobutanil, not to exceed 3,000 parts per billion for in	
	<u> </u>	any concentration for inhalation.	•
	(49)	Naled, not to exceed 500 parts per billion for ingestion of	or 250 parts per billior
	<u> </u>	for inhalation.	<u> </u>
	(50)	Oxamyl, not to exceed 500 parts per billion for ingestio	n or inhalation.
	(51)	Paclobutrazol, not to exceed 100 parts per billion for in	
	(52)	Pentachloronitrobenzene, not to exceed 200 parts per b	
	<u>(52)</u>	150 parts per billion for inhalation.	inten for ingestion of
	(53)	Permethrin, not to exceed 1,000 parts per billion for inge	estion or 100 parts per
	<u>(55)</u>	billion for inhalation.	estion of 100 parts per
	(54)	Phosmet, not to exceed 200 parts per billion for inges	tion or 100 parts per
	<u>(J+)</u>	billion for inhalation.	stion of 100 parts per
	(55)	Piperonyl butoxide, not to exceed 3,000 parts per bi	llion for ingostion of
	<u>(55)</u>	inhalation.	mon for ingestion of
	(56)		stion on 100 nonte no
	<u>(56)</u>	Prallethrin, not to exceed 400 parts per billion for inge	stion or 100 parts per
		billion for inhalation.	• • • 100 •
	<u>(57)</u>	Propiconazole, not to exceed 1,000 parts per billion for	ingestion or 100 parts
	(= -)	per billion for inhalation.	
	<u>(58)</u>	Propoxur, not to exceed 100 parts per billion for ingesti	
	<u>(59)</u>	Pyrethrins, not to exceed 1,000 parts per billion for inge	estion or 500 parts per
		billion for inhalation.	
	<u>(60)</u>	Pyridaben, not to exceed 3,000 parts per billion for inge	estion or 200 parts per
		billion for inhalation.	
	<u>(61)</u>	Spinetoram, not to exceed 3,000 parts per billion for ing	estion or 200 parts per
		billion for inhalation.	
	(62)	Spinosad A & D, not to exceed 3,000 parts per billior	for ingestion or 100
	(02)	<u>Beinosaa II a D; not to exceed 5,000 parts per</u> binior	1 IOI III COLIOII OI 100

	General Assemb	ly Of North Carolina	Session 2023
1 2	<u>(63)</u>	Spiromesifen, not to exceed 3,000 parts per billion for in per billion for inhalation.	ngestion or 100 parts
2 3 4	<u>(64)</u>	Spirotetramat, not to exceed 3,000 parts per billion for in per billion for inhalation.	ngestion or 100 parts
5	<u>(65)</u>	Spiroxamine, not to exceed 100 parts per billion for inge	stion or inhalation.
6	(66)	Tebuconazole, not to exceed 1,000 parts per billion for in	
7		per billion for inhalation.	
8 9	<u>(67)</u>	Thiacloprid, not to exceed 100 parts per billion for inges billion for inhalation.	stion or 100 parts per
10	<u>(68)</u>	Thiamethoxam, not to exceed 1,000 parts per billion for i	ngestion or 500 parts
11		per billion for inhalation.	
12	<u>(69)</u>	Trifloxystrobin, not to exceed 3,000 parts per billion for i	ngestion or 100 parts
13		per billion for inhalation.	
14	<u>(70)</u>	1,2-Dichloroethane, not to exceed 2 parts per million.	
15	<u>(71)</u>	<u>1,1-Dichloroethene, not to exceed 8 parts per million.</u>	
16	$\frac{(72)}{(72)}$	Acetone, not to exceed 750 parts per million.	
17	$\frac{(73)}{(74)}$	Acetonitrile, not to exceed 60 parts per million.	
18	$\frac{(74)}{(75)}$	Benzene, not to exceed 1 part per million.	
19 20	$\frac{(75)}{(76)}$	Butane, not to exceed 5,000 parts per million.	
20 21	<u>(76)</u> (77)	<u>Chloroform, not to exceed 2 parts per million.</u> Ethanol, not to exceed 5,000 parts per million.	
21	$\frac{(77)}{(78)}$	Ethyl Acetate, not to exceed 400 parts per million.	
22	$\frac{(78)}{(79)}$	Ethyl Ether, not to exceed 500 parts per million.	
23 24	$\frac{(72)}{(80)}$	Ethylene Oxide, not to exceed 5 parts per million.	
25	<u>(81)</u>	Heptane, not to exceed 5,000 parts per million.	
26	(82)	Hexane, not to exceed 250 parts per million.	
27	(83)	Isopropyl Alcohol, not to exceed 500 parts per million.	
28	(84)	Methanol, not to exceed 250 parts per million.	
29	<u>(85)</u>	Methylene Chloride, not to exceed 125 parts per million.	<u>.</u>
30	<u>(86)</u>	Pentane, not to exceed 750 parts per million.	
31	<u>(87)</u>	Propane, not to exceed 5,000 parts per million.	
32	<u>(88)</u>	Toluene, not to exceed 150 parts per million.	
33	<u>(89)</u>	Trichloroethylene, not to exceed 25 parts per million.	
34	<u>(90)</u>	Xylenes, Total (ortho-, meta-, para-), not to exceed 150 p	· · · · ·
35	<u>(91)</u>	Cadmium, not to exceed 500 parts per billion for ingest	tion or 200 parts per
36		billion for inhalation.	
37	$\frac{(92)}{(92)}$	Lead, not to exceed 500 parts per billion for ingestion or	
38	<u>(93)</u>	Arsenic, not to exceed 1,500 parts per billion for ingest	tion or 200 parts per
39 40	(0.1)	billion for inhalation.	tion on 200 norts non
40 41	<u>(94)</u>	Mercury, not to exceed 3,000 parts per billion for inges billion for inhalation.	tion of 200 parts per
41 42	<u>(95)</u>	Shiga toxin-producing Escherichia coli (STEC E. coli) a	and other nathogenic
43	<u>())</u>	E. coli, not to exceed 1 CFU per gram.	and other pathogenic
44	<u>(96)</u>	Salmonella, not to exceed 1 CFU per gram.	
45	(97)	Aspergillus niger, Aspergillus fumigatus, Aspergillus	flavus. Aspergillus
46	<u></u>	terreus, not to exceed 1 CFU per gram.	
47	<u>(98)</u>	Total Aflatoxin (B1, B2, G1, G2), not to exceed 20	parts per billion for
48		ingestion or inhalation.	<u></u>
49	<u>(99)</u>	Ochratoxin, not to exceed 20 parts per billion for ingestion	on or inhalation.
50	(100)	Total combined Yeast and Mold, not to exceed 100,00	0 CFU per gram for
51		ingestion and inhalation.	

	General Assem	bly Of North Carolina	Session 2023		
1	(c) Labo	ratory Qualifications. – A manufacturer or distributor shal	ll contract with an		
2	independent testing laboratory to provide the testing required under subsection (a) of this section.				
3	(d) Testing Method. – A laboratory providing testing required under subsection (a) of this				
4		high-performance liquid chromatography for any separation			
5	required in the te				
6		Testing. – A sample of each batch manufactured shall u	ndergo the testing		
7		ection (a) of this section and shall obtain a certificate of analy			
8	· · · · · · · · · · · · · · · · · · ·	ied under subsection (c) of this section. The size of sample re	• • •		
9	shall be determin	ned by the size of the batch as follows:	*		
10	(1)	For a batch containing 1 to 999 units, the required sample	size is one unit.		
11	(2)	For a batch containing 1,000 to 4,999 units, the required	sample size is two		
12		units.	-		
13	<u>(3)</u>	For a batch containing 5,000 to 9,999 units, the required s	ample size is three		
14		units.	-		
15	<u>(4)</u>	For a batch containing 10,000 or more units, the required	sample size is five		
16		units.	*		
17	(f) Expir	ation Date A hemp-derived consumable product shall have	e an expiration date		
18	on the label that	conforms with applicable federal law.			
19	(g) <u>Civil</u>	Penalties A violation of this section shall result in the Dep	artment taking one		
20	or more of the fo	llowing actions against the licensee:			
21	<u>(1)</u>	Suspend the licensee's license for a specified period of time	me not longer than		
22		three years.			
23	<u>(2)</u>	Revoke the licensee's license.			
24	<u>(3)</u>	Impose conditions on the operating hours of the licensee's	business.		
25	<u>(4)</u>	Impose civil penalties as follows:			
26		a. For a first violation, impose a civil penalty of	no more than one		
27		thousand dollars (\$1,000).			
28		b. For a second violation within three years, impose a	civil penalty of no		
29		more than five thousand dollars (\$5,000).			
30		c. For a third violation within three years of the first	-		
31		civil penalty of no more than seven thousand five	ve hundred dollars		
32		<u>(\$7,500).</u>			
33		promise. – In any case in which the Department is entitled to	-		
34 25		or distributor's license, the Department may accept from the			
35		fer in compromise to pay a penalty of not more than eigh			
36		epartment may either accept a compromise or revoke a license			
37		accept a compromise and suspend the license in the same ca			
38		<u>eds of Civil Penalty. – The clear proceeds of any civil pena</u>			
39 40		uding any penalty received as an offer in compromise, shall	be remitted to the		
40 41		d Forfeiture Fund in accordance with G.S. 115C-457.2.	~.		
41 42	•	rtment Duties. – The Department shall do all of the following Maintain and post on its website a registry of testing la			
42 43	<u>(1)</u>				
43 44		<u>qualified to test intermediate manufactured mater</u> hemp-derived consumable products.	ial and finished		
44 45	( <b>2</b> )	Develop an application and process to determine qualifying	a laboratorias to ba		
45 46	<u>(2)</u>	listed on the Department's website. The application shall re-			
40 47		qualifying laboratory to submit a sample certificate of ana	· · ·		
48		applying laboratory.	ayoro rosuca by are		
49	"8 18D-105 /	Additional requirements and restrictions for hemp-der	rived consumable		
<del>5</del> 0	<u>x 10D-105.</u> prod		trea consumable		
50	<u>prou</u>				

General Assem	bly Of	North Carolina	Session 2023
(a) Pack	aging R	equirements. – A hemp-derived consun	nable product that is sold in this
		the following requirements:	
<u>(1)</u>		product shall satisfy the child-resistant $\epsilon$	effectiveness standards under 16
<u>\1)</u>		R. § $1700.15(b)(1)$ when tested in accord	
		R. § 1700.20.	ance with the requirements of ro
<u>(2)</u>		product shall be labeled with consumer	protection warnings in the form
(2)		tements that cover all of the following:	protection warnings in the form
	<u>a.</u>	A list of ingredients and possible aller	rgens and a nutritional fact nanel
	<u>u.</u>	or have a code that can be scanned that	• •
		containing the list of ingredients	
		nutritional fact panel.	and possible anorgous and a
	<u>b.</u>	A statement that use while pregnant of	r breastfeeding may be harmful
	<u>c.</u>	A statement that consumption of ce	
	<u>e.</u>	your ability to drive and operate heav	• •
	<u>d.</u>	A statement that the product is not app	
	<u>u.</u>	and Drug Administration.	sloved by the officed States 1 ood
	e	A statement to keep out of reach of ch	nildren
	<u>e.</u> <u>f.</u>	A statement to consult your physician	
	<u>r.</u> g.	If the product is ingestible, the amou	
	<u>æ.</u>	in each serving of the product, measu	-
	<u>h.</u>	The total amount of hemp-derived ca	
	<u></u>	measured in milligrams.	<u> </u>
	i.	The net weight of the product.	
	<u>i.</u> j.	A code that can be scanned to access a	a website providing the product's
	<u></u>	batch number, date received, date	· · ·
		analysis for the testing required under	-
	k.	An expiration date in accordance with	
(b) Adve		Restrictions. – A manufacturer, distribu	
	-	all not advertise, market, or offer for sa	•
*		e product or product packaging or in ad	· · ·
		ress, trademarks, branding, or other re-	
		gnifies characters or symbols known to a	
21 years of age,	includi	ng, but not limited to, superheroes, con	nic book characters, video game
characters, telev	ision sh	ow characters, movie characters, mythic	cal creatures, and unicorns.
<u>(c)</u> <u>Non-</u>	Liquid	Ingestible Product Restrictions A	Any hemp-derived consumable
product intended	l for ing	estion that is not a liquid and not intende	ed for inhalation shall not do any
of the following	<u>:</u>	-	- -
<u>(1)</u>	Be so	old in a serving that contains more than	25 milligrams, in the aggregate,
	of on	e or more of the following hemp-derived	d cannabinoids:
	<u>a.</u>	Delta-9 tetrahydrocannabinol.	
	<u>b.</u>	Delta-7 tetrahydrocannabinol.	
	<u>c.</u>	Delta-8 tetrahydrocannabinol.	
	<u>d.</u>	Delta-10 tetrahydrocannabinol.	
<u>(2)</u>	Be fo	rmed in the shape of an animal or carto	on character.
<u>(c1)</u> Liqui	d Inge	stible Product Restrictions Any hen	np-derived consumable product
intended for inge	estion th	at is a liquid and not intended for inhala	tion shall not be sold in a serving
that contains m	ore tha	n 10 milligrams, in the aggregate, of	one or more of the following
hemp-derived ca			
<u>(1)</u>		-9 tetrahydrocannabinol.	
<u>(2)</u>		-7 tetrahydrocannabinol.	
<u>(3)</u>	Delta	-8 tetrahydrocannabinol.	

General	Assem	bly Of North Carolina	Session 2023
	(4)	Delta-10 tetrahydrocannabinol.	
(c2)		able Product Restrictions. – Any hemp-derived	d consumable product intended for
		not be sold in a container that contains more	
		the aggregate, of one or more of the followin	
	(1)	Delta-9 tetrahydrocannabinol.	<u> </u>
	(2)	Delta-7 tetrahydrocannabinol.	
	(3)	Delta-8 tetrahydrocannabinol.	
	$\overline{(4)}$	Delta-10 tetrahydrocannabinol.	
<u>(d)</u>		Penalties. – A violation of this section shall re	esult in the Department taking one
		ollowing actions against the licensee:	<u> </u>
	(1)	Suspend the licensee's license for a specifi	ed period of time not longer than
	<u></u>	three years.	<b></b>
	(2)	Revoke the licensee's license.	
	$\overline{(3)}$	Impose conditions on the operating hours o	f the licensee's business.
	(4)	Impose civil penalties as follows:	
	<u> </u>	a. For a first violation, impose a civ	vil penalty of no more than one
		thousand dollars (\$1,000).	<u>, , , , , , , , , , , , , , , , ,</u>
		b. For a second violation within three	years, impose a civil penalty of no
		more than five thousand dollars (\$5	
		c. For a third violation within three ye	
		civil penalty of no more than seve	-
		(\$7,500).	
<u>(e)</u>	Com	promise. – In any case in which the Departme	ent is entitled to suspend or revoke
a manufa		s or distributor's license, the Department may	-
distribut	or an o	ffer in compromise to pay a penalty of not	more than eight thousand dollars
(\$8,000)	. The D	epartment may either accept a compromise or	revoke a license, but not both. The
Departm	ent may	y accept a compromise and suspend the license	e in the same case.
<u>(f)</u>	Proc	eeds of Civil Penalty The clear proceeds of	f any civil penalty imposed under
this secti	on, inc	luding any penalty received as an offer in cor	npromise, shall be remitted to the
Civil Per	nalty an	d Forfeiture Fund in accordance with G.S. 115	<u>5C-457.2.</u>
" <u>§ 18D-</u> 1		<u>Conduct on licensed premises.</u>	
<u>(a)</u>	Certa	ain Conduct. – It shall be unlawful for a lie	censee or the licensee's agent or
<u>employe</u>	e to kn	owingly allow any of the following kinds of	conduct to occur on the licensed
premises	<u>:</u>		
	<u>(1)</u>	Any violation of this Chapter.	
	<u>(2)</u>	Any violation of the controlled substances.	, gambling, or any other unlawful
		acts.	
<u>(b)</u>	-	ervision. – It shall be unlawful for a permittee	to fail to superintend in person or
-		ger the business for which a license is issued.	
" <u>§ 18D-</u> 1		Safe harbor protection for goods not sold in	State.
<u>(a)</u>	<u>This</u>	Article shall not apply to the following:	
	<u>(1)</u>	A safe harbor hemp product.	
	<u>(2)</u>	A safe harbor manufacturer or storage facil	
<u>(b)</u>		the purposes of this section, a "Safe Ha	-
		ompound or cannabinoid, whether a finished	
-		is permitted to be manufactured for distrib	-
		istribution, processed for distribution, prepa	
		nsported for distribution, or held for distribu-	•
		blina but that is not permitted to be sold or dist	-
<u>(c)</u>		he purposes of this section, a "Safe Harbor I	
means a	tacility	y that manufactures for distribution, produc	es tor distribution, packages for

	General Assem	oly Of North Carolina	Session 2023
1	distribution, proc	cesses for distribution, prepares for distribution, treats for dist	tribution, transports
2		or holds for distribution a Safe Harbor Hemp Product.	· <u> </u>
3	"§ 18D-106. Co	nstruction of Article.	
4		is Article shall be construed to do any of the following:	
5	(1)	Permit a person to undertake any task under the influence	of a hemp-derived
6		consumable product when doing so would constitu	<b>*</b>
7		professional malpractice.	<u> </u>
8	<u>(2)</u>	Permit a person to operate, navigate, or be in actual physica	l control of a motor
9		vehicle, aircraft, motorized watercraft, or any other vehic	
10		influence of a hemp-derived consumable product.	
11	<u>(3)</u>	Require an employer to accommodate the use of a hemp-d	lerived consumable
12		product in a workplace or an employee working while und	der the influence of
13		a hemp-derived consumable product.	
14	<u>(4)</u>	Require an individual or establishment in lawful possess	sion of property to
15		admit a guest, client, customer, or other visitor who is imp	
16		the person's use of a hemp-derived consumable product.	
17	<u>(5)</u>	Exempt a person from prosecution for a criminal offense rel	lated to impairment
18		or intoxication resulting from the use of a hemp-derived c	-
19		or relieve a person from any requirement under law to s	submit to a breath,
20		blood, urine, or other test to detect the presence of a control	olled substance.
21	<u>(6)</u>	Limit the ability of an employer to establish, continue, or	enforce a drug-free
22		workplace program or policy.	
23	<u>(7)</u>	Create a cause of action against an employer for wron	ngful discharge or
24		discrimination.	
25	<u>(8)</u>	Allow the possession, sale, manufacture, or distribution of	f any substance that
26		is otherwise prohibited by Article 5 of Chapter 90 of the C	General Statutes.
27		" <u>Article 3.</u>	
28		" <u>Licensing.</u>	
29	" <u>§ 18D-300. De</u>	<u>finitions.</u>	
30		ns contained in Article 1 of this Chapter apply to this Article	e as appropriate.
31	" <u>§ 18D-301. Lio</u>	censing requirements; qualifications; duration.	
32		irement Prior to the commencement of business or by July	
33	-	or entity engaged in this State in any business regulated b	• •
34	listed in this sub	section shall obtain a license to engage in that business fro	m the Department.
35	Businesses enga	ging in one or more of the following are required to obtain a	license pursuant to
36	this section:		
37	<u>(1)</u>	Manufacturing hemp-derived consumable products.	
38	<u>(2)</u>	Distributing hemp-derived consumable products.	
39	<u>(3)</u>	Selling hemp-derived consumable products.	
40		fications In order to obtain and maintain a license under su	ubsection (a) of this
41	section, a person	shall meet all of the following criteria:	
42	<u>(1)</u>	Be at least 21 years old.	
43	<u>(2)</u>	Submit to the Department any information determined by	
44		be necessary for the efficient enforcement of this Chapter.	
45	<u>(3)</u>	Have not been convicted of a felony relating to a controlle	ed substance within
46		<u>10 years in any state or federal jurisdiction.</u>	
47	<u>(4)</u>	Consent to reasonable inspection by the ALE Division of	
48		products regulated by this Chapter to ensure compliance	•
49		and the taking of samples found to not be in compliance v	with the packaging,
50		labeling, and testing requirements of this section.	

General Assemb	ly Of North Carolina	Session 202
<u>(5)</u>	Be current in filing all applicable tax returns to the	e State and in payment of al
	taxes, interest, and penalties collectable pursuant	to G.S. 105-241.22.
(c) Single	e License Required A person or entity engage	d in more than one of the
businesses listed	in subsection (a) of this section shall only be require	ed to obtain a single license
Upon application	for a license, the person or entity engaged in mor	e than one type of busines
regulated by this	Chapter must indicate on the license application a	ll of the businesses listed i
subsection (a) of	this section in which the business engages, or inte	nds to engage. A person o
entity applying for	or a license for more than one type of business list	ted in subsection (a) of thi
section shall pay	a single fee as provided in G.S. 18D-302(c).	
(d) Durat	ion A license issued pursuant to this Article is va	alid for a period of one yea
and may be renev	ved annually.	
" <u>§ 18D-302. Fee</u>	<u>s.</u>	
(a) Appli	cation Fee. – The application fee for a license requ	ired pursuant to this Article
shall be as follow	' <u>S:</u>	-
<u>(1)</u>	For a license to manufacture hemp-derived con	<u>sumable products, a fee o</u>
	fifteen thousand dollars (\$15,000). However, if an	applicant submits proof that
	the applicant's gross income for the calendar year	prior to application was les
	than one hundred thousand dollars (\$100,000), th	e fee shall be one thousand
	<u>dollars (\$1,000).</u>	
<u>(2)</u>	For a license to distribute hemp-derived consum	able products, a fee of tw
	thousand five hundred dollars (\$2,500). Howev	er, if an applicant submit
	proof that the applicant's gross income for t	he calendar year prior t
	application was less than one hundred thousand	
	shall be seven hundred fifty dollars (\$750.00).	
<u>(3)</u>	For a license to sell hemp-derived consumable pro	oducts at a retail location, o
	online for delivery to a person within this State,	
	dollars (\$250.00) for each location or each intern	
	in this State. However, a single entity with more	
	websites offering delivery in this State, or comb	
	pay more than five thousand dollars (\$5,000) and	
	locations and all internet websites offering de	
	Department.	-
(b) Renew	val Fee. – The renewal fee for a license issued purs	suant to this Article shall b
as follows:	*	
(1)	For a license to manufacture hemp-derived const	umable products, a renewa
	fee of five thousand dollars (\$5,000).	*
<u>(2)</u>	For a license to distribute hemp-derived consuma	ble products, a renewal fe
	of seven hundred fifty dollars (\$750.00).	• · · ·
<u>(3)</u>	For a license to sell hemp-derived consumable pr	oducts at a retail location of
<u>,</u>	online for delivery to a person within this State.	
	amount as the initial licensing fees established u	
	section.	
(c) For a	application for or renewal of a license to engage	in more than one busines
	on (a) of G.S. 18D-301, the fee shall be the highest	
	ness indicated on the application or renewal, as	-
licensee.	ness materies on the approaction of fene war, as	appriou to that appriount of
	partment authority to deny or revoke.	
	ent may revoke or refuse to issue any license for an	v of the following:
	ent may revoke or refuse to issue any license for an Failure to comply with or meet any of the	

General Assen	nbly Of North Carolina	Session 2023
(2)	Submission of false or misleading information in an applica	tion for licensure
	or renewal.	
<u>(3)</u>	Submission of false or misleading information in any repo	ort or information
	required by this Chapter to be submitted to the Department.	
<u>(4)</u>	Failure to comply with civil penalties authorized by this Cha	apter.
" <u>§ 18D-304.</u> C	ivil penalties; procedure.	· ·
Proceeding	s for the assessment of civil penalties authorized in Article 1 of	this Chapter shall
be governed by	y Chapter 150B of the General Statutes. If the person or entity	y assessed a civil
penalty fails to	pay the penalty to the Department, the Department may institut	te an action in the
superior court	of the county in which the person resides or has their principal	place of business
to recover the	unpaid amount of the penalty. An action to recover a civil p	enalty under this
Chapter shall n	ot relieve any party from any other penalty prescribed by law.	
" <u>§ 18D-305. D</u>	epartment to develop application, adopt rules, remit revenu	ie.
(a) Lice	ense application. – The Department shall develop and make av	vailable online an
application for	the license required by this Article.	
<u>(b)</u> <u>Rul</u>	es The Department shall have authority to adopt, amend, ar	nd repeal rules to
carry out the pr	ovisions of this Chapter.	
(c) Dist	ribution of Revenue The revenue collected from fees estab	olished under this
-	be remitted to the ALE Division, on a monthly basis, to be use	
	ALE Division in enforcing the provisions of this Chapter. To the	
described in th	is subsection are deemed unappropriated, the funds are hereby	appropriated for
the purpose set	forth in this subsection.	
	" <u>Article 4.</u>	
	"Enforcement.	
" <u>§ 18D-400. A</u>		
	hority The Alcohol Law Enforcement Division of the Depa	
	force the provisions of this Chapter in a manner that is reasona	
	hemp-derived consumable products are sold or distributed to	-
	and shall conduct random, unannounced inspections at	
	consumable products are sold or distributed to ensure com	
-	this Chapter. If, upon reasonable inspection, the ALE Division	
	tory may consist of products not in compliance with the packag	
	nents of this Chapter, the ALE Division is authorized to only t	•
	ntory of hemp-derived consumable products considered nor	±
	esting in order to determine compliance with the provisions of	
-	ce of violations of this Chapter, ALE Division agents shall l	
	operation of each licensee under this Chapter and each licen	
	has been issued under this Chapter, to make inspections that inc	
	s, including the examination of records, equipment, and proceed	
	distribution of hemp-derived consumable products. The inspect	
	y be made at any time it reasonably appears that someone is on	<b>-</b>
	rference with Inspection. – Refusal by a licensee or by any emplo	-
	Division agents to enter the premises to make an inspection	
	of this section shall be cause for suspension, revocation, or other	
	l be a Class 2 misdemeanor for any person to resist or obstruct an	agent attempting
	al inspection under this section.	
	ALE Division shall report to the Department of Revenue any	
•	nich civil penalties are authorized, regardless of whether crimi	nal charges have
been filed.		
	ort. – Beginning January 1, 2026, the ALE Division shall submi	÷
to the General	Assembly describing in detail the ALE Division's enforcement	efforts under this

	General Assemb	oly Of North Carolina	Session 2023
1	Chapter. The AL	E Division shall also make the report required und	er this subsection available
2	on the ALE Divi		
3	" <u>§ 18D-401.</u> For	rfeiture of property.	
4	(a) Seizu	re of Product. – For any hemp-derived consumable	product subject to forfeiture
5	a law enforceme	nt officer is hereby authorized and empowered to s	eize and take possession of
6	such products.		
7	(b) Custo	dy until Trial. – A law enforcement officer seizing a	product subject to forfeiture
8	shall provide for	its safe storage until trial.	
9	(c) Dispo	sition after Criminal Trial. – The presiding judge in	n a criminal proceeding for
10		. 18D-103(a)(3) may take the following actions a	
11	against the owne	r or possessor of products subject to forfeiture under	
12	<u>(1)</u>	If the owner or possessor of the product is fou	• •
13		<u>G.S. 18D-103(a)(3)</u> , the judge shall order the prod	
14	<u>(2)</u>	If the owner or possessor of the product is found r	
15		dismissed or otherwise resolved in favor of the ov	
16		shall order the product returned to the owner or po	
17	<u>(3)</u>	If the product is also needed as evidence at an	-
18		judge shall provide that the order does not go into	-
19		determines that the product is no longer need	led for the administrative
20		proceeding.	
21		sition after Civil Forfeiture Proceeding. – Violati	
22		o forfeiture under the procedure set forth in G.S. 75	
23		sition of Forfeited Product. – Notwithstanding G.S.	. /5D-5(j), a judge ordering
24	· · ·	perty shall order the product destroyed.	
25		n of Property. – Any owner of products seized for	• • • • •
26		products returned to the owner if no criminal charge	·
27 28		e has been commenced in connection with that produce yidge may not order the return of the product if pos	
28 29	be unlawful."	guage may not order the return of the product if pos	session by the owner would
30		<b>FION 1.(b)</b> G.S. 18B-500(b) reads as rewritten:	
31		ct Matter Jurisdiction. – After taking the oath presc	ribed for a peace officer an
32		reement agent shall have authority to arrest and ta	
33		ons for any criminal offense:	ake other investigatory and
34	(1)	Occurring, encountered, or otherwise discovered	ed on the premises of or
35	(1)	elsewhere when the conduct relates to, a location	-
36		holding a permit issued by the North Carolina A	11
37		Commission or the North Carolina Education Lot	-
38	<u>(1a)</u>	Occurring, encountered, or otherwise discovered	-
39	<u> </u>	elsewhere when the conduct relates to, a location	-
40		pursuant to Chapter 18D of the General Statutes.	
41	(2)	Encountered or otherwise discovered while invest	igating or enforcing matters
42	( )	for the North Carolina Alcoholic Beverage Control	0 0
43		Carolina Education Lottery Commission or	
44		discovered while investigating or enforcing the	
45		Chapter 18C of the General Statutes, Chapter 18	
46		G.S. 14-313, or Parts 1 and 2 of Article 37 of	
47		Statutes.	-
48	(3)	Encountered or otherwise discovered while carryi	ng out any duty or function
49		assigned to the Division by law.	
50	(4)	Occurring in an agent's presence.	
51	(5)	When assisting another law enforcement agency."	,

# General Assembly Of North Carolina

2       "(a) In every criminal case in the superior or district court, wherein the defendant is         3       convicted, or enters a plea of guilty or nolo contendere, or when costs are assessed against the         4       prosecuting witness, the following costs shall be assessed and collected. No costs may be         5       assessed when a case is dismissed. Only upon entry of a written order, supported by findings of         6       fact and conclusions of law, determining that there is just cause, the court may (i) waive costs         7       assessed under this section or (ii) waive or reduce costs assessed under subdivision (7), (8), (8a),         8       (11), (12), or (13) of this section. No court may waive or remit all or part of any court fines or         9       costs without providing notice and opportunity to be heard by all government entities directly         10       affected. The court shall provide notice to the government entities directly affected of (i) the date         11       and time of the hearing and (ii) the right to be heard and make an objection to the remission or         12       waiver of all or part of the order of court costs at least 15 days prior to hearing. Notice shall be         13       made to the government entities affected by first-class mail to the address provided for receipt of         13       court costs paid pursuant to the order. The costs referenced in this subsection are listed below:         15          16       (14)
4       prosecuting witness, the following costs shall be assessed and collected. No costs may be         5       assessed when a case is dismissed. Only upon entry of a written order, supported by findings of         6       fact and conclusions of law, determining that there is just cause, the court may (i) waive costs         7       assessed under this section or (ii) waive or reduce costs assessed under subdivision (7), (8), (8a),         8       (11), (12), or (13) of this section. No court may waive or remit all or part of any court fines or         9       costs without providing notice and opportunity to be heard by all government entities directly         10       affected. The court shall provide notice to the government entities directly affected of (i) the date         11       and time of the hearing and (ii) the right to be heard and make an objection to the remission or         12       waiver of all or part of the order of court costs at least 15 days prior to hearing. Notice shall be         13       made to the government entities affected by first-class mail to the address provided for receipt of         14       Eor the services of any laboratory facility, the district or superior court judge         17       shall, upon conviction, order payment of the sum of six hundred dollars         18       (\$600.00) to be remitted to the Alcohol Law Enforcement Division of the         19       Department of Public Safety (ALE Division) or agency that paid for the
<ul> <li>assessed when a case is dismissed. Only upon entry of a written order, supported by findings of fact and conclusions of law, determining that there is just cause, the court may (i) waive costs assessed under this section or (ii) waive or reduce costs assessed under subdivision (7), (8), (8a), (11), (12), or (13) of this section. No court may waive or remit all or part of any court fines or costs without providing notice and opportunity to be heard by all government entities directly affected. The court shall provide notice to the government entities directly affected of (i) the date and time of the hearing and (ii) the right to be heard and make an objection to the remission or waiver of all or part of the order of court costs at least 15 days prior to hearing. Notice shall be made to the government entities affected by first-class mail to the address provided for receipt of court costs paid pursuant to the order. The costs referenced in this subsection are listed below: <li></li> <li>16 (14) For the services of any laboratory facility, the district or superior court judge shall, upon conviction, order payment of the sum of six hundred dollars (\$600.00) to be remitted to the Alcohol Law Enforcement Division of the Department of Public Safety (ALE Division) or agency that paid for the</li> </li></ul>
6fact and conclusions of law, determining that there is just cause, the court may (i) waive costs7assessed under this section or (ii) waive or reduce costs assessed under subdivision (7), (8), (8a),8(11), (12), or (13) of this section. No court may waive or remit all or part of any court fines or9costs without providing notice and opportunity to be heard by all government entities directly10affected. The court shall provide notice to the government entities directly affected of (i) the date11and time of the hearing and (ii) the right to be heard and make an objection to the remission or12waiver of all or part of the order of court costs at least 15 days prior to hearing. Notice shall be13made to the government entities affected by first-class mail to the address provided for receipt of14court costs paid pursuant to the order. The costs referenced in this subsection are listed below:1516(14)17For the services of any laboratory facility, the district or superior court judge18(\$600.00) to be remitted to the Alcohol Law Enforcement Division of the19Department of Public Safety (ALE Division) or agency that paid for the
assessed under this section or (ii) waive or reduce costs assessed under subdivision (7), (8), (8a), (11), (12), or (13) of this section. No court may waive or remit all or part of any court fines or costs without providing notice and opportunity to be heard by all government entities directly affected. The court shall provide notice to the government entities directly affected of (i) the date and time of the hearing and (ii) the right to be heard and make an objection to the remission or waiver of all or part of the order of court costs at least 15 days prior to hearing. Notice shall be made to the government entities affected by first-class mail to the address provided for receipt of court costs paid pursuant to the order. The costs referenced in this subsection are listed below: 16 (14) For the services of any laboratory facility, the district or superior court judge shall, upon conviction, order payment of the sum of six hundred dollars (\$600.00) to be remitted to the Alcohol Law Enforcement Division of the Department of Public Safety (ALE Division) or agency that paid for the
<ul> <li>(11), (12), or (13) of this section. No court may waive or remit all or part of any court fines or costs without providing notice and opportunity to be heard by all government entities directly affected. The court shall provide notice to the government entities directly affected of (i) the date and time of the hearing and (ii) the right to be heard and make an objection to the remission or waiver of all or part of the order of court costs at least 15 days prior to hearing. Notice shall be made to the government entities affected by first-class mail to the address provided for receipt of court costs paid pursuant to the order. The costs referenced in this subsection are listed below:</li> <li></li> <li>16 (14) For the services of any laboratory facility, the district or superior court judge shall, upon conviction, order payment of the sum of six hundred dollars (\$600.00) to be remitted to the Alcohol Law Enforcement Division of the Department of Public Safety (ALE Division) or agency that paid for the</li> </ul>
<ul> <li>costs without providing notice and opportunity to be heard by all government entities directly affected. The court shall provide notice to the government entities directly affected of (i) the date and time of the hearing and (ii) the right to be heard and make an objection to the remission or waiver of all or part of the order of court costs at least 15 days prior to hearing. Notice shall be made to the government entities affected by first-class mail to the address provided for receipt of court costs paid pursuant to the order. The costs referenced in this subsection are listed below:</li> <li></li> <li>16 (14) For the services of any laboratory facility, the district or superior court judge shall, upon conviction, order payment of the sum of six hundred dollars (\$600.00) to be remitted to the Alcohol Law Enforcement Division of the Department of Public Safety (ALE Division) or agency that paid for the</li> </ul>
10affected. The court shall provide notice to the government entities directly affected of (i) the date11and time of the hearing and (ii) the right to be heard and make an objection to the remission or12waiver of all or part of the order of court costs at least 15 days prior to hearing. Notice shall be13made to the government entities affected by first-class mail to the address provided for receipt of14court costs paid pursuant to the order. The costs referenced in this subsection are listed below:1516(14)17For the services of any laboratory facility, the district or superior court judge18(\$600.00) to be remitted to the Alcohol Law Enforcement Division of the19Department of Public Safety (ALE Division) or agency that paid for the
11and time of the hearing and (ii) the right to be heard and make an objection to the remission or12waiver of all or part of the order of court costs at least 15 days prior to hearing. Notice shall be13made to the government entities affected by first-class mail to the address provided for receipt of14court costs paid pursuant to the order. The costs referenced in this subsection are listed below:1516(14)17For the services of any laboratory facility, the district or superior court judge18(\$600.00) to be remitted to the Alcohol Law Enforcement Division of the19Department of Public Safety (ALE Division) or agency that paid for the
<ul> <li>waiver of all or part of the order of court costs at least 15 days prior to hearing. Notice shall be</li> <li>made to the government entities affected by first-class mail to the address provided for receipt of</li> <li>court costs paid pursuant to the order. The costs referenced in this subsection are listed below:</li> <li></li> <li><u>16</u> (<u>14</u>) For the services of any laboratory facility, the district or superior court judge</li> <li>shall, upon conviction, order payment of the sum of six hundred dollars</li> <li>(\$600.00) to be remitted to the Alcohol Law Enforcement Division of the</li> <li><u>19</u> Department of Public Safety (ALE Division) or agency that paid for the</li> </ul>
<ul> <li>made to the government entities affected by first-class mail to the address provided for receipt of court costs paid pursuant to the order. The costs referenced in this subsection are listed below:</li> <li></li> <li><u>(14)</u> For the services of any laboratory facility, the district or superior court judge shall, upon conviction, order payment of the sum of six hundred dollars (\$600.00) to be remitted to the Alcohol Law Enforcement Division of the Department of Public Safety (ALE Division) or agency that paid for the</li> </ul>
14court costs paid pursuant to the order. The costs referenced in this subsection are listed below:1516(14)17For the services of any laboratory facility, the district or superior court judge17shall, upon conviction, order payment of the sum of six hundred dollars18(\$600.00) to be remitted to the Alcohol Law Enforcement Division of the19Department of Public Safety (ALE Division) or agency that paid for the
1516(14)17For the services of any laboratory facility, the district or superior court judge17shall, upon conviction, order payment of the sum of six hundred dollars18(\$600.00) to be remitted to the Alcohol Law Enforcement Division of the19Department of Public Safety (ALE Division) or agency that paid for the
16(14)For the services of any laboratory facility, the district or superior court judge17shall, upon conviction, order payment of the sum of six hundred dollars18(\$600.00) to be remitted to the Alcohol Law Enforcement Division of the19Department of Public Safety (ALE Division) or agency that paid for the
17shall, upon conviction, order payment of the sum of six hundred dollars18(\$600.00) to be remitted to the Alcohol Law Enforcement Division of the19Department of Public Safety (ALE Division) or agency that paid for the
18(\$600.00) to be remitted to the Alcohol Law Enforcement Division of the19Department of Public Safety (ALE Division) or agency that paid for the
19 Department of Public Safety (ALE Division) or agency that paid for the
20 laboratory services. The cost shall be assessed only in cases in which (i) the
20 <u>laboratory services. The cost shall be assessed only in cases in which (i) the</u> 21defendant is convicted of a violation of G.S. 18D-103(a)(3) and (ii) as part of
22 the investigation leading to the defendant's conviction, testing was conducted
23 <u>at a laboratory on products regulated under Chapter 18D of the General</u>
24 <u>Statutes.</u> "
25 <b>SECTION 1.(d)</b> This section becomes effective July 1, 2025, and applies to all
26 hemp-derived consumable products possessed, sold, distributed, or manufactured on or after that
27 date, and to all offenses committed on or after that date.
28 SECTION 1.1.(a) Subchapter I of Chapter 105 of the General Statutes is amended
29 by adding a new Article to read:
30 " <u>Article 5K.</u>
31 " <u>Hemp-Derived Consumable Products Tax.</u>
32 " <u>§ 105-187.96. Tax imposed.</u>
33 (a) Levy and Rate. – An excise tax at the rate of ten and one-half percent (10.5%) is
34 imposed on the retail sale of a hemp-derived consumable product. The tax is in addition to any
35 tax imposed under any other provision of federal, State, or local law. For purposes of this Article,
36 the term "hemp-derived consumable product" is as defined in G.S. 18D-100.
37 (b) Trust Tax. – The tax imposed by this Article is intended to be passed on to and borne
38 by the purchaser of the hemp-derived consumable product. The tax is a debt from the purchaser
39 to the retailer until paid and is recoverable at law by the retailer in the same manner as other
40 debts. A retailer is considered to act as a trustee on behalf of the State when it collects tax from
<ul> <li>41 <u>the purchaser on a taxable transaction. The tax must be stated and charged separately on any</u></li> <li>42 documentation provided to the purchaser by the retailer at the time of the transaction.</li> </ul>
<ul> <li>42 <u>documentation provided to the purchaser by the retailer at the time of the transaction.</u></li> <li>43 "<u>§ 105-187.97. Registration.</u></li> </ul>
44 (a) <u>Requirement and Application. – A retailer of hemp-derived consumable products that</u>
45 is not otherwise registered with the Department pursuant to G.S. 105-164.29 must register with
46 the Department.
47 (b) Issuance. – A certificate of registration is not assignable and is valid only for the
48 person in whose name it is issued. A copy of the certificate of registration must be displayed at
49 each place of business.
50 (c) <u>Term. – A certificate of registration is valid unless it is revoked for failure to comply</u>
51 with the provisions of this Article or becomes void. A certificate issued to a person who makes

	General Assem	bly Of North Carolina	Session 2023
1	taxable sales or	a person liable for tax under this Article becc	omes void if, for a period of 18
2	months, the pers	on files no returns or files returns showing no s	ales.
3	(d) Revo	cation. – The failure of a retailer to comply	with this Article is grounds for
4	revocation of th	e person's certificate of registration. Before the	he Secretary revokes a person's
5		gistration, the Secretary must notify the persor	• •
6	-	icate of registration and that the proposed revo	• • • •
7		ts to the proposed revocation and files a request f	
8		.S. 105-241.11 for requesting a Departmental re	
9		be sent in accordance with the methods auth	<b>- -</b>
10		ticle 9 of this Chapter for review of a proposed	•
11	of a proposed rev		
12		Administration.	
13		nerwise provided in this Article, the tax imposed	by this Article shall be collected
14	_	l in the same manner as the State sales and use ta	-
15		ovisions of Article 9 of this Chapter that are no	± •
16		istration, auditing, making returns, promulgatio	
17		onal taxes, assessments and assessment procedu	
18		n thereof, and penalties, are made a part of this	
19	thereto.	<u></u>	
20		Exemptions and refunds.	
21		ons and refunds allowed in Article 5 of this Cl	hapter do not apply to sales that
22		constitutionally tax."	
23		<b>FION 1.1.(b)</b> This section becomes effective J	July 1, 2025, and applies to sales
24	occurring on or a		,,
25			
26	PART II. TECH	HNICAL CHANGES	
27		<b>TION 2.(a)</b> G.S. 90-94.1 is repealed.	
28		<b>TION 2.(b)</b> This section becomes effective D	ecember 1, 2024, and applies to
29		ted on or after that date.	, , , , , , , , , , , , , , , , , , ,
30	011011505000111111		
31	PART III. APP	ROPRIATION	
32		<b>TION 3.(a)</b> The following sums are appropriat	ted from the General Fund to the
33		ublic Safety in nonrecurring funds for the 2024	
34	(1)	Two million dollars (\$2,000,000) to be used	
35	( )	positions in the Alcohol Law Enforcement	-
36		Public Safety (ALE Division) to serve as	1
37		implementing the provisions of this act. Upo	1 0
38		fees remitted to the ALE Division pursuant	
39		Statutes, as enacted by this act, shall be use	-
40		recurring basis.	
41	(2)	Three hundred seventy-five thousand dollars	s (\$375.000) to be used for any
42	(-)	other costs incurred by the Department of	
43		provisions of this act.	
44	(3)	One hundred twenty-five thousand dollars (\$	125.000) to be used for any other
45		costs incurred by the ALE Division in implem	· · · ·
46	SEC	<b>TION 3.(b)</b> Any nonrecurring funds appropriate	<b>e</b> 1
47		I year that remain unexpended at the end of the	1 V
48		of the 2024-2025 fiscal year and shall remain	-
49		the funds were appropriated until the funds a	-
50		<b>TION 3.(c)</b> This section is effective July 1, 202	-

50 51

	General Assembly Of North Carolina Session 2	023
1	PART IV. PROHIBIT USE OF HEMP-DERIVED CONSUMABLE PRODUCTS	ON
2	SCHOOL GROUNDS	on
3	<b>SECTION 4.(a)</b> The title of Article 29A of Chapter 115C of the General Stat	utes
4	reads as rewritten:	aces
5	"Article 29A.	
6	"Policy Prohibiting Use Of Tobacco Tobacco and Hemp-Derived Consumable Products.	•
7	<b>SECTION 4.(b)</b> G.S. 115C-407 reads as rewritten:	
8	"§ 115C-407. Policy prohibiting tobacco use in school buildings, grounds, and	at
9	school-sponsored events.	
10	(a) Not later than August 1, 2008, local boards of education Governing bodies of pu	blic
11	school units shall adopt, implement, and enforce adopt a written policy prohibiting at all ti	
12	the use of any tobacco product by any person in school buildings, in school facilities, on sc	
13	campuses, and in or on any other school property owned or operated by the local sc	
14	administrative public school unit. The policy shall further prohibit the use of all tobacco prod	
15	by persons attending a school-sponsored event at a location not listed in this subsection whe	
16	the presence of students or school personnel or in an area where smoking is otherwise prohib	
17	by law.	neu
18	(b) The policy shall include at least all of the following elements:	
19	(i) Adequate notice to students, parents, the public, and school personnel of	the
20	policy.	
21	(2) Posting of signs prohibiting at all times the use of tobacco products by	anv
22	person in and on school property.	5
23	(3) Requirements that school personnel enforce the policy.	
24	(c) The policy may permit tobacco products to be included in instructional or rese	arch
25	activities in public school buildings if the activity is conducted or supervised by the fac	
26	member overseeing the instruction or research and the activity does not include smok	•
27	chewing, or otherwise ingesting the tobacco product.	0
28	(d) The North Carolina Health and Wellness Trust Fund Commission shall work	with
29	local boards of education to provide assistance with the implementation of this policy inclu	ling
30	providing information regarding smoking cessation and prevention resources. Nothing in	this
31	section, G.S. 143-595 through G.S. 143-601, or any other section prohibits a local boar	<del>l of</del>
32	education governing body of a public school unit from adopting and enforcing a more restrict	
33	policy on the use of tobacco in school buildings, in school facilities, on school campuses,	or at
34	school-related or school-sponsored events, and in or on other school property."	
35	SECTION 4.(c) Article 29A of Chapter 115C of the General Statutes is amende	d by
36	adding a new section to read:	
37	"§ 115C-407.1. Policy prohibiting use of hemp-derived consumable products in sc	<u>100l</u>
38	buildings, grounds, and at school-sponsored events.	
39	(a) For purposes of this section, the following definition applies:	
40	(1) <u>Hemp-derived consumable product. – As defined in G.S. 18D-100.</u>	
41	(b) Governing bodies of public school units shall adopt a written policy prohibiting a	
42	times the use of any hemp-derived consumable product by any person in school building	
43	school facilities, on school campuses, on school buses or school transportation service vehi	
44	and in or on any other school property owned or operated by the public school unit. The po	
45	shall further prohibit the use of all hemp-derived consumable products by persons attendi	-
46	school-sponsored event at a location not listed in this subsection when in the presence of stud	
47	or school personnel or in an area where the use of hemp-derived consumable produc	<u>s is</u>
48	otherwise prohibited by law.	
49	(c) The policy shall include at least all of the following elements:	
50	(1) Adequate notice to students, parents, the public, and school personnel of	the
51	<u>policy.</u>	

	General Assembly Of North Carolina	Session 2023
1	(2) Posting of signs prohibiting at all times the use of hemp-de	rived consumable
2	products by any person in and on school property.	
3	(3) Requirements that school personnel enforce the policy.	
4	(d) The policy may permit hemp-derived consumable products to	be included in
5	instructional or research activities in public school buildings if the activity	is conducted or
6	supervised by the faculty member overseeing the instruction or research and the	
7	include smoking, chewing, or otherwise ingesting or inhaling the hemp-der	-
8	product.	
9	(e) Nothing in this section, G.S. 143-595 through G.S. 143-601, or a	any other section
10	prohibits a governing body of a public school unit from adopting and enforcing	a more restrictive
11	policy on the use of hemp-derived consumable products in school buildings, ir	n school facilities,
12	on school campuses, or at school-related or school-sponsored events, and in c	or on other school
13	property."	
14	SECTION 4.(d) G.S. 115C-218.75 is amended by adding a new su	
15	"(a1) Policies Prohibiting Use of Tobacco, Hemp-Derived Consumab	le Products. – A
16	charter school shall adopt policies prohibiting use of tobacco and hemp-den	rived consumable
17	products in school buildings, grounds, on school buses or school transportation	n service vehicles,
18	and at school-sponsored events in accordance with Article 29A of this Chapter	
19	SECTION 4.(e) G.S. 115C-238.66 is amended by adding a new su	bdivision to read:
20	"(7h) Policies prohibiting use of tobacco and hemp-derived consu	
21	A regional school shall adopt policies prohibiting use	of tobacco and
22	hemp-derived consumable products in school buildings, gr	counds, on school
23	buses or school transportation service vehicles, and at	school-sponsored
24	events in accordance with Article 29A of this Chapter."	
25	<b>SECTION 4.(f)</b> G.S. 115C-150.12C is amended by adding a ne	ew subdivision to
26	read:	
27	"(15a) Policies prohibiting use of tobacco and hemp-derived consu	
28	The board of trustees shall adopt policies prohibiting use	
29	hemp-derived consumable products in school buildings, gr	
30	buses or school transportation service vehicles, and at	school-sponsored
31	events in accordance with Article 29A of this Chapter."	
32	<b>SECTION 4.(g)</b> G.S. 116-239.8(b) is amended by adding a new su	
33	"(9a) Policies prohibiting use of tobacco and hemp-derived consu	
34	The chancellor shall adopt policies prohibiting use	
35	hemp-derived consumable products in school buildings, gr	
36	buses or school transportation service vehicles, and at	
37	events in accordance with Article 29A of Chapter 1150	<u>C of the General</u>
38	Statutes."	
39	<b>SECTION 4.(h)</b> Subdivision (21) of Section 6(d) of S.L. 2018-32 t	
40	"(21) Article 29A, Policy Prohibiting Use of Tobacco-Tobacco and	nd Hemp-Derived
41	Consumable Products."	
42	<b>SECTION 4.(i)</b> This section is effective when it becomes law and	applies beginning
43	with the 2025-2026 school year.	
44		
45 46	PART V. MISCELLANEOUS	idanaa ( ('
46 47	<b>SECTION 5.(a)</b> The Department of Revenue shall establish gu	-
47 10	regulated by the provisions of Chapter 18D of the General Statutes, as enacted	
48 40	Department shall adopt and amend rules prior to July 1, 2025, however, no	•
49 50	effective until on or after that date. The Department shall provide and accep	applications for

licensure, and issue licenses in accordance with Chapter 18D of the General Statutes, as enacted
by this act, prior to July 1, 2025, in order that licensees may be in compliance with the provisions

#### **General Assembly Of North Carolina**

1 of Chapter 18D of the General Statutes on July 1, 2025. No license issued by the Department 2 shall become effective prior to July 1, 2025. The Department of Revenue may use the procedure 3 set forth in G.S. 150B-21.1 to adopt or amend any rules as required under this section. 4 SECTION 5.(b) The Department of Public Safety shall adopt rules, or amend their 5 rules, consistent with the provisions of this act. The Department of Public Safety may use the 6 procedure set forth in G.S. 150B-21.1 to adopt or amend any rules as required under this section. 7 8 PART VI. ADD TIANEPTINE, XYLAZINE, AND KRATOM TO THE CONTROLLED 9 SUBSTANCE SCHEDULES 10 **SECTION 6.(a)** G.S. 90-90 reads as rewritten: 11 "§ 90-90. Schedule II controlled substances. This schedule includes the controlled substances listed or to be listed by whatever official 12 13 name, common or usual name, chemical name, or trade name designated. In determining that a 14 substance comes within this schedule, the Commission shall find: a high potential for abuse; currently accepted medical use in the United States, or currently accepted medical use with severe 15 16 restrictions; and the abuse of the substance may lead to severe psychic or physical dependence. 17 The following controlled substances are included in this schedule: 18 19 (2)Any of the following opiates or opioids, including their isomers, esters, ethers, 20 salts, and salts of isomers, whenever the existence of such isomers, esters, 21 ethers, and salts is possible within the specific chemical designation unless 22 specifically exempted or listed in other schedules: 23 . . . 24 bb. Tianeptine. ...." 25 26 SECTION 6.(b) G.S. 90-91 reads as rewritten: 27 "§ 90-91. Schedule III controlled substances. 28 This schedule includes the controlled substances listed or to be listed by whatever official 29 name, common or usual name, chemical name, or trade name designated. In determining that a 30 substance comes within this schedule, the Commission shall find: a potential for abuse less than 31 the substances listed in Schedules I and II: currently accepted medical use in the United States; 32 and abuse may lead to moderate or low physical dependence or high psychological dependence. 33 The following controlled substances are included in this schedule: 34 . . . 35 (b) Any material, compound, mixture, or preparation which contains any quantity of the 36 following substances having a depressant effect on the central nervous system unless specifically 37 exempted or listed in another schedule: 38 Any substance which contains any quantity of a derivative of barbituric acid, 1. 39 or any salt of a derivative of barbituric acid. 40 2. Chlorhexadol. 3. Repealed by Session Laws 1993, c. 319, s. 5. 41 42 4. Lysergic acid. 43 5. Lysergic acid amide. Methyprylon. 44 6. 45 7. Sulfondiethylmethane. 46 8. Sulfonethylmethane. 47 Sulfonmethane. 9. 48 9a. Tiletamine and zolazepam or any salt thereof. Some trade or other names for 49 tiletamine-zolazepam combination product: Telazol. Some trade or other names for tiletamine: 50

	General Assem	ably Of North Carolina	Session 2023
1 2 3		2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Some tr zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trin 1,4]/y-diazepin-7(1H)-one. flupyrazapon.	
4	10.	Any compound, mixture or preparation containing	
5	10.	(i) Amobarbital.	
6		(ii) Secobarbital.	
7		(iii) Pentobarbital.	
8		or any salt thereof and one or more active ingredients	which are not included
9		in any other schedule.	
10	11.	Any suppository dosage form containing	
11		(i) Amobarbital.	
12		(ii) Secobarbital.	
13		(iii) Pentobarbital.	
14		or any salt of any of these drugs and approved by the	federal Food and Drug
15		Administration for marketing as a suppository.	C C
16	12.	Ketamine.	
17	<u>13.</u>	Xylazine.	
18	"		
19	SEC	<b>CTION 6.(c)</b> G.S. 90-94 reads as rewritten:	
20	"§ 90-94. Sche	dule VI controlled substances.	
21	(a) This	schedule includes the controlled substances listed or to	be listed by whatever
22	official name, c	ommon or usual name, chemical name, or trade name des	ignated. In determining
23	that such substa	nce comes within this schedule, the Commission shall fine	d: no currently accepted
24	medical use in t	he United States, or a relatively low potential for abuse in	n terms of risk to public
25	<b>1</b>	ntial to produce psychic or physiological dependence liab	• • •
26	medical knowle	edge, or a need for further and continuing study to develo	p scientific evidence of
27	its pharmacolog		
28	(b) The	following controlled substances are included in this sche	dule:
29	(1)	Marijuana.	
30	(2)	Tetrahydrocannabinols, except for tetrahydrocannabin	
31		with a delta-9 tetrahydrocannabinol concentration	
32		three-tenths of one percent $(0.3\%)$ on a dry weight bas	
33	(3)	Repealed by Session Laws 2017-115, s. 8, effective	
34		applicable to offenses committed on or after that date.	
35	<u>(4)</u>	Kratom. For the purposes of this subdivision, "Kratom	
36		of mitragynine or 7-hydroxymytragynine or both, ex	tracted from the leaf of
37		the plant mitragyna speciosa.	
38	" GE(		1 2024 1 1' (
39 40		<b>CTION 6.(d)</b> This section becomes effective December	1, 2024, and applies to
40	offenses commi	itted on or after that date.	
41			NT A NID TINIT A WITTIT
42		REATE THE OFFENSE OF CRIMINAL POSSESSIO	
43 44		BALMING FLUID AND TO MAKE OTHER TECHN TION 7.(a) This section of the act shall be known as "	
44 45	Embalming Flu		The Kakim Shackleford
43 46	•	<b>CTION 7.(b)</b> G.S. 90-210.20 reads as rewritten:	
40 47	"§ 90-210.20. ]		
47	-	ng definitions apply in this Article:	
48 49		<u>)</u> "Advertisement" means the <u>Advertisement. – The</u> pub	lication dissemination
49 50	<del>(a)</del>	circulation or placing before the public, or causing dir	
50 51		made, published, disseminated or placed before the public	
51		made, published, disseminated of placed before the pu	one, any announcement

	General Assemb	ly Of North Carolina	Session 2023
1		or statement in a newspaper, magazine, or other publication, o	or in the form of
2		a book, notice, circular, pamphlet, letter, handbill, poster, bil	
3		card, label or tag, or over any radio, television station, or elec	tronic medium.
4	<del>(b)</del> (2)	"Board" means the Board The North Carolina Board of Fur	neral Service.
5	$\overline{(c)}\overline{(3)}$	"Burial" includes Burial. – Includes interment in any form, cr	emation and the
6		transportation of the dead human body as necessary therefor.	
7	<del>(c1)(4)</del>	<u>"Chapel" means a Chapel. – A chapel or other facility sep</u>	parate from the
8		funeral establishment premises for the primary purpose of re-	eposing of dead
9		human bodies, visitation or funeral ceremony that is owned	ed, operated, or
10		maintained by a funeral establishment under this Article, and t	hat does not use
11		the word "funeral" in its name, on a sign, in a directory, in a	dvertising or in
12		any other manner; in which or on the premises of which there	is not displayed
13		any caskets or other funeral merchandise; in which or on t	the premises of
14		which there is not located any preparation room; and wh	nich no owner,
15		operator, employee, or agent thereof represents the chapel	to be a funeral
16		establishment.	
17	<del>(c2)(5)</del>	<u>"Dead human bodies", as used in this Article includes Dead h</u>	uman bodies. –
18		Includes fetuses beyond the second trimester and the ashes	from cremated
19		bodies.	
20	<del>(d)<u>(</u>6)</del>	"Embalmer" means any Embalmer Any person engaged in	the practice of
21		embalming.	
22	<del>(e)<u>(7)</u></del>	"Embalming" means the Embalming The preservation and	
23		attempted preservation and disinfection of dead human bodies	• • •
24		of chemicals externally or internally or both and the practice of	
25		including the restoration or attempted restoration of the appea	
26		human body. Embalming shall not include the washing or u	-
27		water to cleanse or prepare a dead human body for disp	•
28		authorized agents, family, or friends of the deceased who	
29		without pay or as part of the ritual washing and preparation	
30		bodies prescribed by religious practices; provided, that no de	
31	$\langle 0 \rangle$	shall be handled in a manner inconsistent with G.S. 130A-395	
32	<u>(8)</u>	Embalming fluid. – Any chemicals or substances manufacture	
33		use by licensed funeral directors, undertakers or embalmer	-
34 25		residents to prepare, disinfect, or preserve, either hypodermi	
35 26		or by any other recognized means, the body of a deceased per	erson for burial,
36 37	(a1)(0)	cremation, or other final disposition.	on Entry layol
38	<del>(E1)</del> (9)	<u>) "Entry level examination in funeral directing" means</u>	
38 39		<u>examination in funeral directing. – An</u> examination (i) offered of a final or capstone course in a mortuary science program a	
40		Board or (ii) accredited by the American Board of Funeral Se	
40 41		or an examination equivalent to the State Board Examination	
42		Directing to assess competency in <u>all of the following subject</u>	
42 43		(1) <u>a.</u> Funeral arranging and directing.	5.
44		(1) <u>a.</u> Funeral service marketing and merchandising.	
45		(3) <u>c.</u> Funeral service counseling.	
46		(4) <u>d.</u> Legal and regulatory compliance.	
40 47		( <del>5)</del> ). Cemetery and crematory operations.	
48	<del>(£)</del> (10)	"Funeral directing" means engaging <u>Funeral directing. – E</u>	Ingaging in the
49	(1)(10)	practice of funeral service except embalming.	<u>mgagnig</u> in the
50	<del>(a)</del> (11)	<u>) "Funeral director" means any Funeral director. – Any person</u>	engaged in the
51	(8) <u>(11</u>	practice of funeral directing.	
51		praetice of functur anothing.	

(h)(12) "Funeral establishment" means every Funeral establishment. – Every place of premises devoted to or used in the care, arrangement and preparation for th funeral and final disposition of dead human bodies and maintained for th convenience of the public in connection with dead human bodies or as the convenience of the public in connection with dead human bodies.
premises devoted to or used in the care, arrangement and preparation for th funeral and final disposition of dead human bodies and maintained for th
convenience of the public in connection with dead human bodies or as the
convenience of the public in connection with dead number bodies of as the
place for carrying on the practice of funeral service.
(i)(13) "Funeral service licensee" means a person who is duly licensed and engage
in the practice of funeral service. Funeral service The aggregate of a
funeral service licensees and their duties and responsibilities in connectio
with the funeral as an organized, purposeful, time-limited, flexible
group-centered response to death.
(j)(14) "Funeral service" means the aggregate of all funeral service licensees and the
duties and responsibilities in connection with the funeral as an organized
purposeful, time-limited, flexible, group-centered response to death.Funera
service licensee. – A person who is duly licensed and engaged in the practic
of funeral service.
(k)(15) "Practice of funeral service" means engaging Practice of funeral service.
Engaging in the care or disposition of dead human bodies or in the practice of
disinfecting and preparing by embalming or otherwise dead human bodies for
the funeral service, transportation, burial or cremation, or in the practice of
funeral directing or embalming as presently known, whether under these title
or designations or otherwise. "Practice of funeral service" also mean
engaging in making arrangements for funeral service, selling funeral supplie
to the public or making financial arrangements for the rendering of suc
services or the sale of such supplies.
(1)(16) "Resident trainee" means a Resident trainee. – A person who is engaged i
preparing to become licensed for the practice of funeral directing, embalmin
or funeral service under the personal supervision and instruction of a perso
duly licensed for the practice of funeral directing, embalming or funeral
service in the State of North Carolina under the provisions of this Chapter, an
who is duly registered as a resident trainee with the Board."
<b>SECTION 7.(c)</b> Article 13A of Chapter 90 of the General Statutes is amended b
adding a new section to read:
" <u>§ 90-210.29C. Unlawful sale of embalming fluid.</u>
(a) <u>Offense. – It is unlawful for a funeral director, embalmer, or resident trainee t</u>
knowingly give, sell, permit to be sold, offer for sale, or display for sale, other than for purpose
within the general scope of their activities as a funeral director, embalmer, or resident trained
embalming fluid to another person with actual knowledge that the person is not a funeral director
embalmer, or resident trainee.
(b) Punishment. – A person who violates subsection (a) of this section is guilty of a Class
I felony, including a fine of not less than one hundred dollars (\$100.00) and not more than five
hundred dollars (\$500.00)."
<b>SECTION 7.(d)</b> Chapter 90 of the General Statutes is amended by adding a new
Article to read:
" <u>Article 5H.</u>
" <u>Miscellaneous Drug-Related Regulations.</u>
" <u>§ 90-113.107. Criminal possession of embalming fluid.</u>
(a) <u>Definition. – For purposes of this section, the following terms are as defined i</u>
$\underline{G.S. 90-210.20:}$ (1) Each choice
(1) Embalmer.
(2) Embalming.
(3) <u>Embalming fluid.</u>

	General A	Asseml	bly Of North Carolina	Session 2023
1		(4)	Funeral director.	
2		(5)	Resident trainee.	
3	<u>(b)</u>		use. – Both of the following are unlawful:	
4	<u>+</u>	(1)	Possessing embalming fluid for any purpose other than th	e lawful preservation
5		<u> </u>	of dead human bodies by a person authorized by law to er	
6			or the lawful preservation of wildlife by a person lie	
7			pursuant to G.S. 113-273(k).	
8		<u>(2)</u>	Selling, delivering, or otherwise distributing embalm	ing fluid to another
9		<u>1</u> =7	person with knowledge that the person intends to utilize	•
10			for any purpose other than the lawful preservation of dea	
11			person authorized by law to engage in such activity or th	
12			of wildlife by a person licensed in taxidermy pursuant to	
13	<u>(c)</u>	Punis	hment. – A person who commits a violation of subsection	
14			l as follows:	
15	· · · · · ·	(1)	If the violation involves less than 28 grams, the violation	shall be punished as
16		<u>, - 7</u>	a Class I felony.	<u> </u>
17		(2)	If the violation involves 28 grams or more of embalmin	g fluid, but less than
18		<u> </u>	200 grams, the violation shall be punished as a Class G f	-
19		(3)	If the violation involves 200 grams or more of embalmir	· · · · · · · · · · · · · · · · · · ·
20		<u> </u>	400 grams, the violation shall be punished as a Class F f	-
21		<u>(4)</u>	If the violation involves 400 grams or more of embalmir	
22		<u></u>	shall be punished as a Class D felony.	<u> </u>
23	(d)	Const	truction. – Nothing in this section shall be construed as pr	rohibiting possession
24	of embali		luid by, or selling, delivering, or otherwise distributing	
25			s, embalmers, resident trainees, or licensed taxidermists	
26	embalmin	<u>ıg.</u> "		
27		SEC	<b>FION 7.(e)</b> G.S. 90-96.2(c3) reads as rewritten:	
28	"(c3)	Cove	red Offenses A person shall have limited immunity fro	m prosecution under
29	subsections (b) and (c) of this section for only the following offenses:			
30		(1)	A misdemeanor violation of G.S. 90-95(a)(3).	
31		(2)	A felony violation of G.S. 90-95(a)(3) for possession of	less than one gram of
32			any controlled substance.	
33		(3)	Repealed by Session Laws 2023-123, s. 3, effective De	cember 1, 2023, and
34			applicable to offenses committed on or after that date.	
35		<u>(3a)</u>	A violation of G.S. 90-113.107 punishable as a Class I fe	elony.
36		(4)	A violation of G.S. 90-113.22."	
37		SEC	<b>FION 7.(f)</b> This section becomes effective December 1,	2024, and applies to
38	offenses c	commit	ted on or after that date.	
39				
40			REATE NEW CRIMINAL OFFENSES FOR EXPOSIN	NG A CHILD TO A
41	CONTRO		D SUBSTANCE	
42			<b>FION 8.(a)</b> Article 39 of Chapter 14 of the General Sta	atutes is amended by
43	U		ction to read:	
44			posing a child to a controlled substance.	
45	<u>(a)</u>	-	itions. – The following definitions apply in this section:	
46		<u>(1)</u>	<u>Child. – Any person who is less than 16 years of age.</u>	
47		<u>(2)</u>	Controlled substance. – A controlled substance, c	
48			analogue, drug, marijuana, narcotic drug, opiate, opioid,	
49 50			straw, or targeted controlled substance, all as defined in	
50		<u>(3)</u>	Ingest. – Any means used to take into the body, to eat o	or drink, or otherwise
51			consume, or absorb into the body in any way.	

	General Assembly Of North CarolinaSession 2023			
1	(b) A person who knowingly, recklessly, or intentionally causes or permits a child to be			
2	exposed to a controlled substance is guilty of a Class H felony.			
3	(c) <u>A person who knowingly, recklessly, or intentionally causes or permits a child to be</u>			
4	exposed to a controlled substance, and as a result the child ingests the controlled substance, is			
5	guilty of a Class E felony.			
6	(d) <u>A person who knowingly, recklessly, or intentionally causes or permits a child to be</u>			
7	exposed to a controlled substance, and as a result the child ingests the controlled substance,			
8	resulting in serious physical injury, is guilty of a Class D felony.			
9	(e) <u>A person who knowingly, recklessly, or intentionally causes or permits a child to be</u>			
10	exposed to a controlled substance, and as a result the child ingests the controlled substance,			
11	resulting in serious bodily injury, is guilty of a Class C felony.			
12	(f) <u>A person who knowingly, recklessly, or intentionally causes or permits a child to be</u>			
13	exposed to a controlled substance, and as a result the child ingests the controlled substance, and			
14	the ingestion is the proximate cause of death, is guilty of a Class B1 felony."			
15	<b>SECTION 8.(b)</b> This section becomes effective December 1, 2024, and applies to			
16	offenses committed on or after that date.			
17				
18	PART IX. EFFECTIVE DATE			
19	<b>SECTION 9.(a)</b> Prosecutions for offenses committed before the effective date of			
20	this act are not abated or affected by this act, and the statutes that would be applicable but for			
21	this act remain applicable to those prosecutions.			
22	<b>SECTION 9.(b)</b> If any provision of this act or its application is held invalid, the			
23	invalidity does not affect other provisions or applications of this act that can be given effect			
24	without the invalid provisions or application and, to this end, the provisions of this act are			
25	severable.			
26	<b>SECTION 9.(c)</b> Except as otherwise provided, this act is effective when it becomes			
27	law.			